



# Department of Pesticide Regulation



Brian R. Leahy  
Director

## MEMORANDUM

Edmund G. Brown Jr.  
Governor

TO: Shelley DuTeaux, PhD MPH  
Chief  
Human Health Assessment Branch

VIA: Svetlana Koshlukova, PhD  
Senior Toxicologist  
Risk Assessment Section

*[original signed by S. Koshlukova]*

Eric Kwok, PhD DABT  
Senior Toxicologist  
Exposure Assessment Section

*[original signed by E. Kwok]*

FROM: Carolyn M. Lewis, MS DABT  
Research Scientist III (Chemical Sciences)  
Risk Assessment Section

*[original signed by C. Lewis]*

Mai Ngo, PhD  
Staff Toxicologist  
Exposure Assessment Section

*[original signed by M. Ngo]*

Terrell Barry, PhD  
Research Scientist IV  
Exposure Assessment Section

*[original signed by T. Barry]*

DATE: December 22, 2016

SUBJECT: Response to OEHHA's Comments on Dicrotophos Risk Characterization Document  
and Exposure Assessment Document

---

The Office of Environmental Health Hazard Assessment (OEHHA) in the California Environmental Protection Agency reviewed the Risk Characterization Document (RCD) for dicrotophos dated December 30, 2015 that was prepared by the Department of Pesticide Regulation to address a Special Local Need registration (Section 24c). Their comments were summarized in a memorandum dated March 30, 2016. Part I are responses from the Risk Assessment Section to the comments directed at the toxicology issues. These responses are only to the Section III. Detailed Comments to avoid repetition of comments made under Section I. Summary and Section II. Charge Questions. Part II are responses from the Exposure Assessment section to comments directed at exposure related issues.



## **I. SUMMARY OF REVIEW**

*This report presents the review by the Office of Environmental Health Assessment (OEHHA) on the Department of Pesticide Regulation (DPR) draft Risk Characterization Document (RCD) for dicrotophos, an organophosphate pesticide not currently registered in California. The draft RCD characterizes the health risks from dicrotophos associated with a Special Local Need (SLN) registration of BIDRIN® 8 to control brown stink bugs on cotton. Workers and adult residential bystanders were evaluated for dermal, inhalation, and combined exposures. Child bystanders were evaluated for dermal, inhalation, oral, and combined exposures. Dietary and drinking water exposures were also considered for various age groups for the general public. Overall we find the document is well-written and the limited toxicological review is justified for the proposed single use on cotton. Our principal comments are summarized in Section I. Responses to DPR's charge statements (descriptions of scientific assumptions, findings and conclusions to be addressed by peer reviewers) are provided in Section II. Detailed comments are provided in Section III and minor comments are in Section IV.*

### **I.A. Hazard Identification and Risk Characterization**

#### **I.A.1. Non-cancer Endpoint Selection and Point of Departure Determination**

##### **I.A.1.a. Toxicity Endpoint**

- *The draft RCD considered brain cholinesterase inhibition (ChEI) to be the most sensitive health endpoint, and used ChEI data from laboratory animal studies for deriving points of departure (PODs) for all exposure routes and durations. OEHHA generally agrees with the approach to evaluate brain ChEI as the critical effect. However, changes in brain weight in neonatal pups from Brammer (2003) occurred at similarly low doses and DPR should re-evaluate this study and provide reasons for not using it in POD determination.*

**HHAB Response:** Detailed descriptions of the critical studies were added to the Neurotoxicity and Carcinogenicity sections in the RCD, including the developmental neurotoxicity study.

- *The draft RCD showed that dicrotophos inhibition of brain ChEI reaches steady state after about 21 days of repeated dosing. Once steady-state enzyme inhibition is reached, subsequent exposure does not appear to elicit a greater response. Because of this finding, DPR determined it was unnecessary to evaluate repeated exposures using the conventional subchronic and chronic exposure scenarios, when ChEI is the critical effect. Instead, the draft RCD only evaluated acute and steady-state exposures. This is consistent with the US Environmental Protection Agency's (US EPA) risk assessment for dicrotophos (2015a) and OEHHA agrees with this approach.*

**HHAB Response:** No response needed.

- *For brain ChEI, DPR considered rat pups more sensitive than adult rats for acute oral exposure. The draft RCD applied the acute oral POD derived from data for rat pups*

*(postnatal day 8, PND8) to estimate the risk for all population subgroups in the exposure assessments as a conservative approach.*

- *OEHHA agrees with the application of this POD for all subpopulations. The subpopulations evaluated in the exposure assessments for dicrotophos can be divided into: sensitive population and general adult population. The sensitive population consists of infants, children, and women of child-bearing age who could be affected by the developmental neurotoxicity (DNT) of dicrotophos. Individuals in the sensitive population are in the worker (women of child-bearing age), bystander and dietary exposure scenarios. The 'general adult' population in this report include adults (age 50 to 99) for the dietary exposure scenario (this is consistent with US EPA's subpopulation classification in the 2015 risk assessment).*

**DPR RAS Response:** No response needed.

#### ***I.A.1.b. Benchmark Dose Modeling***

- *DPR used Benchmark Dose (BMD) modeling with a benchmark response (BMR) of 10% (BMDL10) to establish the POD for ChEI. OEHHA agrees with the approach. This is consistent with US EPA's recommendation of a 10% BMR for brain ChEI by organophosphate pesticides (OPs) based on both statistical and biological evidence (US EPA, 2015b). OEHHA also agrees with DPR in choosing the Hill model in some of the BMD analyses. By contrast, US EPA only used the Exponential model for ChEI data. OEHHA's opinion is that model selection should be based on which model most accurately describes the data. The exponential and Hill models are typically used for receptor-mediated responses. In a number of cases described in the draft RCD, the Hill model provided a substantially better fit (higher Test 4 p values) than the exponential models.*

**HHAB Response:** No response needed.

- *DPR did not provide sufficient information on why a specific BMD model was selected for POD determination. This is especially important for cases where the models selected failed one or more of the statistical tests in the Benchmark Dose Software (BMDS). As outlined by US EPA (2012a), PODs should be based on models that fit all the criteria for model selection. The draft RCD should include model outputs as well as clearly describe the criteria used for model selection.*

**HHAB Response:** An appendix has been added to the RCD with the results from the BMD batch runs for each data set. The output includes the p-values for Tests 1-4, AIC, scaled residuals, BMD and BMDL values. A footnote was provided under each batch run to explain which criteria were used to select the model highlighted or why a model was not selected.

#### ***I.A.1.c. Oral Exposure***

- *For acute oral exposure, OEHHA agrees with DPR's choice of the BMDL10 of 0.03 milligram/kilogram-day (mg/kg-day) for brain ChEI in PND8 male rats given dicrotophos by gavage (Moxon, 2003) as the acute oral POD for the both the sensitive population and the*

*general adult population. While the BMDL10 for brain ChEI from neonatal rats is lower than for adult animals in the database, OEHHA agrees that the aging brain can also be more sensitive to neurotoxicity than the healthy adult population and a POD from neonatal animals is health protective for these populations.*

**HHAB Response:** Currently HHAB's default intraspecies uncertainty factor (UF) is not designed implicitly to protect the elderly. This presents an interesting dilemma because some of the drugs used to treat Alzheimer's disease are ChE inhibitors. There is a U-shaped curve in the treatment of Alzheimer's with ChE inhibitors, so low levels can be beneficial (hormesis), while higher levels are harmful. At this point, there does not appear to be enough information available about various neurotoxicants and the aging brain to determine if an additional sensitivity UF is needed for the elderly. However, DPR RAS will take this potential age-related sensitivity into consideration when reevaluating the default intraspecies UF.

- *OEHHA agrees with the selection of a BMDL10 of 0.025 mg/kg-day for brain ChEI from the subchronic neurotoxicity study in adult female rats as the steady-state oral POD (Horner, 1995). The BMDL10 of brain ChEI for each of the exposure duration (5, 9 and 14 weeks) was the same (0.025 mg/kg-day), indicating that ChEI reached a steady-state by at least 5 weeks of treatment. The BMDL10s for males in the study were slightly higher (0.031-0.036 mg/kg-day), but reached a steady-state at about the same time.*

**HHAB Response:** No response needed.

#### ***I.A.1.d. Inhalation Exposure***

- *DPR selected a 28-day inhalation toxicity study in the rat (Blair, 2010) as the critical study and used its endpoint (brain ChEI) to assess acute and steady-state dicrotophos inhalation exposures because it was the only appropriate study. While OEHHA agrees with the study selection, OEHHA is concerned about the magnitude of the POD based on the BMDL10 when compared to the study's No-Observed-Effect Levels (NOELs). There is a large difference between the NOEL (<0.097 mg/kg-day) and the BMDL10 (0.41 mg/kg-day) for the female rat. OEHHA suggests additional discussion be added to address these differences and to justify the use of the BMDL10 as the POD. Additionally, the NOEL (estimated at 0.032 µg/L when a factor of 3 is applied to the lowest dose with a significant effect) may be appropriate because of concerns regarding the BMD model selection for this endpoint.*

**HHAB Response:** HHAB disagrees with OEHHA that the NOEL approach should be used over the BMDL approach. In the traditional NOEL/LOEL approach, the threshold dose is dependent on the dose selection in the study. The BMDL approach is particularly useful when a NOEL is not observed, but it is also useful when the dose levels are widely spaced apart. Both of these situations apply in the Blair (2010) study. A NOEL was not observed in the females and the difference between the low and mid-dose level (0.097 and 0.73 µg/L, respectively) is 7.5-fold. Furthermore, if one were to apply an additional uncertainty factor of 3 to account for concerns about the BMD analysis, it should be applied to the BMDL, not the NOEL. DPR RAS did not consider the problems with the BMD analysis to be of sufficient concern to apply an additional

uncertainty factor. Additional discussion of this study and the BMD analysis can be found in the response to the detailed comment III.C.3. in this document.

#### ***I.A.1.e. Dermal Exposure***

- *The toxicity database for dicrotophos also lacked appropriate acute toxicity studies for dermal exposure. Thus, DPR chose a 28-day dermal toxicity study as the critical study and brain ChEI as the critical endpoint for acute and steady-state dermal dicrotophos exposures (Noakes, 2001). The POD was the BMDL10 of 2.1 mg/kg-day. OEHHA concurs with this determination.*

**HHAB Response:** No response needed.

#### ***I.A.2. Carcinogenicity Weight of Evidence***

- *OEHHA agrees with DPR's weight of evidence evaluation for determining the carcinogenicity of dicrotophos. The presence of follicular cell adenomas (benign) only in male mice (Milburn, 1998) and weak mutagenicity in in vitro genotoxicity assays (San and Clark, 1995; Dean, 1974) are insufficient to identify dicrotophos as a carcinogen. Toxicity ForeCaster (ToxCast™) data indicated a lack of carcinogenic potential. However, there is a published genotoxicity study which showed dicrotophos caused an increase in chromosomal aberrations (CA) in CHO-K1 cells and induced DNA damage in HepG2 cells (Wu et al., 2010). OEHHA suggests DPR include this study in their weight of evidence evaluation to reflect a greater concern for the genotoxicity potential of dicrotophos.*

**HHAB Response:** Wu *et al.* (2010) was added to the discussion of the genotoxicity of dicrotophos along with two more studies cited in that article. However, the addition of these data does not change the weight of evidence sufficiently to support a quantitative assessment since there is still only an increase in tumors in one sex and one species in one study.

#### ***I.A.3. Uncertainty Factors and Sensitive Populations***

- *DPR applied a 10-fold interspecies uncertainty factor (UF) for the assumption that humans are 10 times more sensitive than animals. OEHHA agrees with this approach.*

**HHAB Response:** No response needed.

- *In the draft RCD, DPR applied an UF of 10 for intraspecies pharmacokinetic and pharmacodynamic variability for all populations. OEHHA recommends DPR increase the intraspecies factor to 30 for the general adult population. OEHHA uses a default UF of 10 for intraspecies pharmacokinetic variability, which accounts for wide variability by age in pharmacokinetics and thus for subpopulations possibly being more sensitive than the general adult population to the toxicity of a chemical. The scientific basis for this recommendation is detailed in OEHHA's peer reviewed Air Toxics Hot Spots Risk Assessment Guidelines, Technical Support Document for the Derivation of Reference*

*Exposure Levels (OEHHA, 2008). An UF of  $\sqrt{10}$  is retained for intraspecies pharmacodynamic variability.*

**HHAB Response:** For dicotophos, we assumed a default intraspecies factor of 10 that includes a pharmacokinetic UF of  $\sqrt{10}$  and a pharmacodynamic UF of  $\sqrt{10}$ . This is in agreement with the current DPR practice and the approach taken by U.S. EPA both in their 2014 and 2015 health assessment for dicotophos. HHAB is currently revising its own risk assessment guidance, including guidance on when departures from this default may be justified.

- *For the sensitive population (pregnant women, infants, children, and women of child-bearing age), OEHHA recommends an UF of 10 for intraspecies variability. This is supported by a POD derived from effects observed in PND8 animals. However, OEHHA also recommends the use of an additional UF of 10 to protect against DNT (see below). This additional UF would offer additional protection against both pharmacokinetic and pharmacodynamic variability in the sensitive population.*

**HHAB Response:** HHAB recommends the use of an additional 10 UF for sensitive subpopulations.

- *US EPA determined that there was sufficient uncertainty regarding dicotophos' mechanism of action causing developmental neurotoxicity (DNT) that the Food Quality Protection Act (FQPA) 10-fold Safety Factor was applied in their 2015 human risk assessment for dicotophos (US EPA, 2015a). OEHHA concurs with this concern especially when there is evidence of changes in brain weight and morphometry in pups exposed to dicotophos in utero from the Brammer study (2003). OEHHA recommends including this additional uncertainty factor to protect infants.*

**HHAB Response:** HHAB agrees an additional uncertainty for infants, children, and pregnant women is appropriate given the systematic review by U.S. EPA of possible effects of OPs on neurodevelopment by non-ChEI MOAs. These effects are not well understood at this time. However, we do not believe the evidence from the DNT study can be used as further evidence in support of it because of uncertainties regarding the apparent differences in brain weights and morphometric measurements. For more discussion of these uncertainties, see the response to detailed comment III.F.2.c. in this document.

- *Total UFs recommended by OEHHA are 300 for the adult general population (10 for interspecies, 30 for intraspecies) and 1000 for the sensitive population (10 for interspecies, 10 for intraspecies, 10 for DNT).*

**HHAB Response:** For the dicotophos risk assessment, HHAB is proposing to use a total UF of 100 for adults, except women of childbearing age, based on default UF factors of 10 each for intraspecies and interspecies variation. This is consistent with what U.S. EPA used in their 2014 and 2015 dicotophos human health risk assessments. For sensitive population subgroups, DPR RAS is proposing to use a total UF of 1000 to protect infants, children, and women of childbearing age against potential neurodevelopmental effects.

#### ***I.A.4. Risk Characterization***

- *Margin of Exposure (MOE) values are calculated by dividing the POD by the estimated human exposure dose or air concentration. The draft RCD characterized whether an exposure is likely to cause adverse health effects using a target MOE of 100 for all age groups. OEHHA recommends re-evaluation of the target MOEs to take into account the recommended UFs in this report. OEHHA's suggested target MOEs are 300 and 1000 for the general adult population and sensitive population, respectively.*

**HHAB Response:** As stated above, HHAB's current default for intraspecies variation is 10, which is consistent with U.S. EPA's practice.

#### ***I.B. Worker and Bystander Exposure Assessment***

##### ***I.B.1. Occupational Handler Exposure Scenarios***

- *OEHHA agrees that occupational handler exposure estimates based on the Pesticide Handlers Exposure Database (PHED) are reasonable. However, OEHHA is concerned with the continued reliance on PHED, as software for this database is no longer available or supported by US EPA. Secondly, PHED has known limitations, such as exposure estimates that are based on combinations of data from diverse studies that have different protocols, analytical methods and residue detection limits.*
- *OEHHA recommends that DPR consider supplementing PHED data with data from other sources, such as the Agricultural Handlers Exposure Task Force database, whenever possible.*

**HHAB Response:** The Agricultural Handlers Exposure Task Force (AHETF) has provided DPR with the worker exposure database, which HHAB is reviewing for use as surrogate handler exposure estimates when chemical-specific data are unavailable.

- *To improve the transparency of the draft EAD, OEHHA also recommends that DPR cite the specific PHED scenarios, data and calculations used in the exposure estimates.*

**HHAB Response:** To improve transparency, Appendix I with PHED data subsets and detailed mean dermal exposure calculations with protection factors has been provided in the final EAD draft.

##### ***I.B.2. Occupational Post-Application Exposure Scenarios***

- *OEHHA is concerned that the values for transfer coefficient (TC) and dislodgeable foliar residue (DFR) used in the cotton scout scenario might have underestimated exposure.*

**HHAB Response:** As it stands, the TC value of 2000 cm<sup>2</sup>/hr used in this EAD is almost 10 times higher than that used by of U.S. EPA (210 cm<sup>2</sup>/hr). Unacceptable exposure levels will be further addressed during the mitigation process to follow.

- *OEHHA recommends that DPR consider using a TC derived from results of a monocrotophos field study instead of the TC used in the draft EAD that was based on field data from three different pesticides. OEHHA also recommends that DPR address acute and seasonal exposure of cotton scouts, who may enter treated fields prior to the expiration of the re-entry interval (REI) to inspect for insect damage and status of plant development.*

**HHAB Response:** Due to these uncertainties in the data, TC approximations using the monocrotophos data alone were not deemed to be better surrogates than those calculated from the geometric means of the three individual pesticides, ethyl- and methyl-Parathion and monocrotophos. This conclusion was based on limited data from the monocrotophos study where only two time points were provided, and because the TC values derived with monocrotophos were inconsistent with and up to 22 times higher than those for ethyl- and methyl- parathion (Ware *et al.*, 1975; Ware *et al.*, 1973; Ware *et al.*, 1974). Discussion of exposure to cotton scouts prior to the expiration of the REI has now been added to the EAD. Acute and seasonal exposures with early reentry by cotton scouts wearing defined PPE is expected to be lower than exposures calculated for scouts entering after the REI.

- *OEHHA disagrees with the approach taken in the draft EAD in estimating the dermal absorption value of dicrotophos. Rather than relying on a mathematically complex analysis of data from in vivo and in vitro dermal absorption studies in rats and humans, OEHHA recommends that DPR utilize the data from an in vivo dermal absorption study of monocrotophos in human subjects (Feldmann and Maibach, 1974).*

**HHAB Response:** HHAB is very grateful for the monocrotophos reference provided and will include this as support for the current triple-pack analysis under development.

HHAB practice is to use chemical-specific data when available, and surrogate data or default values when high quality chemical-specific data are not available. Since *in vivo* human data are rarely available, it is often necessary to utilize animal studies and rely more and more on *in vitro* data. *In vitro* data is rather variable, influenced by numerous experimental factors such as receptor fluid composition, diffusion cell type, and skin sample preparation. An inter-laboratory study comparing the *in vitro* absorption values for caffeine, testosterone, and benzoic acid generated by 10 independent laboratories found relatively large discrepancy in mean absorption of compounds among the laboratories, even though the same detailed protocol and OECD guidance was followed (van de Sandt *et al.*, 2004). This analysis underscores the challenges of conducting and making direct inferences of dermal absorption from *in vitro* studies. Consistent and detailed experimental guidelines must be followed for an *in vitro* study to be comparable to another. By requiring the same test conditions be used with both the animal and human *in vitro* studies, the “Triple-pack” approach helps to increase predictability and make comparisons between studies appropriate.



Relating the *in vitro* to *in vivo* dermal absorption of a compound from experimental animal studies is one approach to corroborate *in vitro* data. With the “triple-pack” method, if the ratio of the *in vitro* to *in vivo* animal data approaches the value of one (1), one may infer that the *in vitro* test conditions were an appropriate surrogate of *in vivo* absorption process. Secondly, if the *in vitro* test conditions were proven to be “appropriate” and these same test conditions were used to generate absorption data in human skin, there could be greater confidence that those results are directly translatable for evaluating *in vivo* human absorption.

As discussed in the EAD, the *in vitro* dermal absorption studies submitted by the registrant for dicotophos were determined to be usable for the purpose of estimating dermal absorption. Data quality is considered in the triple-pack analysis by calculating the 95% confidence interval of the ratio. In our analysis for dicotophos, the animal *in vitro* to animal *in vivo* ratio was 1.23 with the 95<sup>th</sup> percentile confidence interval of the ratio is estimated to be 0.88-1.59. The variability of the animal data is incorporated into the 95<sup>th</sup> percentile confidence interval calculation for the *in vivo* human dermal absorption.

### ***1.B.3. Residential Bystander Exposure Scenario***

- *OEHHA is concerned about the choice of AgDRIFT input parameters for estimating groundboom-related spray drift deposition, as well as the use of the 50th percentile deposition curve output, as they may lead to underestimation of exposure. OEHHA recommends that DPR provide additional justification for these choices and cite additional literature describing current agricultural practices that support the assumption regarding the larger droplet size. OEHHA also recommends that DPR use the more conservative 90th percentile output option as there appears to be sufficient documentation of the source data and relevant calculations in the publically available literature.*

**HHAB Response:** The 90<sup>th</sup> percentile AgDRIFT estimate for ground boom was not used for 2 reasons:

- a) The orchard airblast are 50<sup>th</sup> percentile estimates and the aerial deposition estimates are ensemble mean estimates. The ground boom should be evaluated on the same basis.
- b) It is correct to state that “...the deposition curves were based on the measured values...” However, according to the methods given in the AgDRIFT user manual (Teske *et al.*, 2003), it appears that the function labeled as the 90<sup>th</sup> percentile function for ground boom was derived by fitting a function only through the 90<sup>th</sup> percentile rank deposition observed at each distance in each scenario (assuming the “bounding value” mentioned in the text means the 90<sup>th</sup> percentile rank value). If this is true, the 90<sup>th</sup> percentile value returned by the function in AgDRIFT will never be larger than what was measured in the field. Unfortunately, it is not known whether any of the measured values in the field studies actually represent the true 90<sup>th</sup> percentile deposition. Thus, it is impossible to conclude that the function represents the true 90<sup>th</sup> percentile deposition at a particular downwind distance. The actual data and process of how the curves were

developed is not given in the AgDRIFT user manual and a detailing of Teske's analysis is not published. As a result, the reader cannot verify the results by repeating the Teske analysis. Thus, the uncertainty associated with the 90<sup>th</sup> percentile function is unknown. In addition, since the 90<sup>th</sup> percentile function in AgDRIFT was not developed using the 50<sup>th</sup> percentile function as a basis, there is no ability provide statistical confidence with which the 90<sup>th</sup> percentile deposition value was captured.

Unlike fitting a function through the 90<sup>th</sup> percentile rank values at each downwind distance, tolerance bounds on the 50<sup>th</sup> percentile function captures a percentile value (e.g. 90<sup>th</sup> percentile) with a known confidence. The width of the tolerance bound depends upon the sample size, variance, and selected confidence level. Barry *et al.* (1999) presented tolerance bounds for the ground boom deposition curves. In addition, Barry (1999a, b) together with OPP staff (U.S. EPA, 1999a) developed tolerance bounds on the ground boom deposition curves using different functions than that selected by Teske *et al.* Those tolerance bounds had known confidence levels. However, those deposition curves and the associated tolerance bounds were not implemented in the AgDRIFT model.

Thus, for dicrotophos the 50<sup>th</sup> percentile ground boom deposition estimate was used because: 1) the orchard airblast and aerial estimates are 50<sup>th</sup> percentile (or ensemble mean) estimates and ground boom should be evaluated on the same basis, 2) Teske's analysis methods cannot be examined in detail, and 3) the confidence (representing the likelihood that the true 90<sup>th</sup> percentile was captured) associated with the 90<sup>th</sup> percentile deposition for ground boom as calculated by the function in AgDRIFT is unknown.

#### ***I.B.4. Non-Occupational Post-Application Exposure Scenarios***

- *OEHHA is concerned that potential dicrotophos exposure via the "take home" dust scenario was not discussed, and recommends that a quantitative evaluation of this scenario be included in the draft EAD.*

**HHAB Response:** This scenario has now been addressed in the revised EAD.

#### ***I.C. Dietary Exposure Assessment***

- *Dietary (food and drinking water) exposure assessments were conducted for acute and steady-state exposures to dicrotophos. The only proposed use of dicrotophos is on cotton and the only food products with potential residue are cottonseed and processed cotton products (including cottonseed oil). OEHHA generally agrees with the approaches taken in the dietary assessment.*

**DPR RAS Response:** No response needed.

- *OEHHA recommends the analysis should be updated to include the most recent version of the exposure software (DEEM-FCID v. 4.02), include exposure estimates for pregnant and*

*lactating women, and remove or clarify the need to derive dietary exposure estimates for “workers 18-99.”*

**HHAB Response:** HHAB did not use the DEEM-FCID version 4.02 in its previous draft since it was a beta-test version that U.S. EPA did not recommend using yet. However, DPR RAS contacted U.S. EPA recently about the status of this version and they said that the final version is to be released in December 2016 and the output of the beta test version should not be numerically different. Based on this information, DPR RAS decided to rerun the dietary and drinking water assessment for dicotophos with 4.02 version. The results were equivocal, with some estimates increasing and others decreasing. The size of the population subgroups was similar to the NHANES 2003-2008 consumption database. Note that U.S. EPA used version 3.16 in their 2014 and 2015 dietary and drinking water assessments for dicotophos.

- *Exposure estimates were described as 95th percentile for dietary, 99.9th percentile for water, and 97.5th combined. OEHHA recommends further explanation on how these percentiles were chosen and on how the exposure estimates for food and drinking water were combined.*

**HHAB Response:** Different percentiles were used depending on the approach. When a deterministic approach is used in the dietary and drinking water assessments, HHAB’s default percentile is the 95<sup>th</sup> percentile. This approach is inherently health protective using the highest residue value. HHAB considers this a Tier 2 approach and used it with the dietary exposure since there were not enough samples to do a more refined approach. When a probabilistic approach is used, HHAB’s default is the 99.9<sup>th</sup> percentile. HHAB considers this a Tier 3 approach. This approach was used with the drinking water assessment since there were more than 100 samples. HHAB’s default percentile is an intermediate percentile of 97.5<sup>th</sup> when the residues files contains a mixture of point estimates (deterministic) and residue distribution files (probabilistic), as was the case when the dietary and drinking water residues were combined.

- *In the Risk Appraisal section of the Draft RCD, DPR showed higher drinking water exposure levels estimated from surface water data than those from using Pesticide Database Program (PDP) finished drinking water data. OEHHA suggests that DPR clarify the wide differences in drinking water exposure estimates between these two data sources and provide justification on which is more appropriate.*

**HHAB Response:** HHAB chose not to use the drinking water modeling data that U.S. EPA generated in its 2015 revised assessment because they did not model environmental conditions in California. The other states that were modeled (Georgia, Texas, and Mississippi) have higher rainfall rates so the environmental modeling results most likely exaggerated the runoff compared to California. U.S. EPA modeled California drinking water exposure in 2014 but not in 2015, presumably because the exposure estimates were the lowest of all the locations modeled. In its 2014 assessment, U.S. EPA provided the mean and high estimates for drinking water exposure in California, but the residue files were not available. If the mean and high estimates from U.S. EPA’s 2014 California model were input in the DEEM-FCID model and a deterministic

approach could be performed, it would likely result in much higher exposure estimates than if a probabilistic approach was used.

## **II. RESPONSES TO CHARGE STATEMENTS**

*The responses to some of the charge statement are intended to be brief to avoid redundancy with the comments in Section I and detailed discussion of OEHHA's comments in Section III.*

### **II.A. Hazard Identification and Risk Characterization**

**Statement 1:** *"A benchmark dose (BMD) analysis was conducted on all of the studies with brain ChE data using the exponential models and the Hill model to identify critical NOELs."*

**OEHHA Response:** *As described in Section I, OEHHA agrees with the selection of the Hill and exponential models because they are designed for receptor-mediated responses. OEHHA recommends the inclusion of model outputs and model selection criteria.*

**HHAB Response:** Appendix III has been added to the RCD with a table summarizing the model outputs for all the BMD batch runs performed for dicrotophos for each study including p-values for tests, AIC, scaled residuals, BMD and BMDL values. The model selected is highlighted and there is a footnote explaining the rationale for that selection or lack of selection of any model.

**Statement 2:** *"A BMDL10 of 0.03 mg/kg-day was selected as the critical NOEL for evaluating acute oral exposure to dicrotophos based on brain ChEI in PND8 rat pups (Moxon, 2003a)."*

**OEHHA Response:** *As described in Section III.C, OEHHA agrees with the study selected for acute oral exposure. .*

*In addition, in this charge statement as well as others, and in the draft RCD, BMDL10 and NOEL were considered equivalent terms as the BMDL10 was referred to as the critical NOEL. They are not. The draft RCD should recognize they represent two different ways to determine the POD.*

**HHAB Response:** Currently HHAB uses the term "critical NOEL" to apply to either a NOEL or BMDL since they are used in the same manner to calculate an MOE. HHAB is considering a change in the terminology to avoid confusion.

**Statement 3:** *"A BMDL of 0.025 mg/kg-day for brain ChEI from the subchronic neurotoxicity study in adult female rats was selected as the critical NOEL to evaluate the steady-oral exposure to dicrotophos (Horner, 1995)."*

**OEHHA Response:** *As described in Section III.C, OEHHA agrees with DPR's selection of 0.025 mg/kg-day (BMDL10) from female adult rats as the steady-state oral POD (Horner, 1995). The chosen POD was also protective of brain ChEI of neonatal animals because the BMDL10 for PND12 rats were at similar level (0.03 mg/kg-day; Moxon, 2003b).*

**HHAB Response:** No response needed.

**Statement 4:** “A BMDL10 of 2.1 mg/kg-day from the 28-day dermal study in rats was selected as the critical NOEL to evaluate dermal exposure for both short-term and steady-state exposures (Noakes, 2001).”

**OEHHA Response:** As described in Section III.C, OEHHA agrees with this determination.

**HHAB Response:** No response needed.

**Statement 5:** “A BMDL10 of 0.42 µg/L (microgram/liter) from the 28-day inhalation study in rats was selected as the critical NOEL to evaluate inhalation exposure for workers and bystanders for all exposure durations (Blair, 2010).”

**OEHHA Response:** OEHHA agrees with the selection of Blair (2010) as the critical study to evaluate inhalation exposure to dicrotophos. However, additional discussion on BMDL10 and NOEL values is needed to explain the significance of the large difference between these values and issues with BMD model selection (see Detailed Comments in Section III.C).

**HHAB Response:** The difference between the NOELs and the BMDLs is likely due to the large spacing between low and mid-dose in this study. This is a good example of why a BMD analysis is preferable over a NOEL approach. Not only were the low and mid-doses widely spaced, but there was no apparent NOEL in the females. The BMD modeling results were not ideal, but the results for all models with both sexes resulted in BMDLs that were greater than 0.35 µg/L, except for one model (Exponential Model 3 in females) which had the worst fit based on Test 4 p-value and AIC. HHAB will accept the model results when the Test 3 p-value is less than 0.1 as long as the 4 p-values are > 0.1 or close to 0.1, especially if the alternative is to use a NOEL. A description of this approach has been added to the BMD analysis and you will find a specific rationale for selecting the BMDL for this study in the footnote for the BMD batch run in Appendix III.

**Statement 6:** “DPR RAS concluded there was insufficient evidence to conduct a quantitative assessment for carcinogenicity based on the increase in thyroid tumors in male mice observed in a 105-week oral oncogenicity study (Milburn, 1998).”

**OEHHA Response:** As described in Section III.E, OEHHA agrees with DPR’s conclusion that there is insufficient evidence to conduct a quantitative cancer analysis. However, OEHHA suggests that the result from the genotoxicity study (Wu, 2010) be included in the genotoxicity potential evaluation.

**HHAB Response:** Please see HHAB response under section I.A.2. Carcinogenicity Weight of Evidence of this memorandum.

## **II.B. Exposure Assessment**

**Statement 7:** *“Dietary and drinking water exposure were evaluated using a deterministic approach with mean residues in cottonseed oil from field trial studies and a probabilistic approach with residues in finished drinking water from the PDP database, respectively.”*

**OEHHA Response:** *OEHHA generally agrees with the approaches taken for dietary exposure to dicrotophos. There are no California specific residue data or drinking water concentrations so OEHHA agrees with DPRs use of registrant submitted field trial residue data and PDP drinking water data. However, OEHHA suggests additional explanation of the percentiles chosen for the dietary and water exposure estimates and the combined exposure.*

**HHAB Response:** Additional explanation of the percentile use in the dietary and drinking water assessment has been added to the discussion of the Exposure Estimates section under the Dietary and Drinking Water Exposure section.

**Statement 8:** *“A mathematical approach in qualifying in vitro dermal absorption data for use in exposure assessment is being used for the first time. Since a peer review of this approach has not been performed, a level of uncertainty is cast upon the dermal exposure estimates.”*

**OEHHA Response:** *The complex mathematical approach that DPR used to estimate the dermal absorption of dicrotophos does not appear to be warranted because a more direct, transparent approach is available. OEHHA recommends that DPR utilize experimental data from an in vivo dermal absorption study of monocrotophos in human subjects (Feldmann and Maibach, 1974) to estimate the dermal absorption of dicrotophos. This alternative approach does not require interspecies extrapolation or appraisal of the validity of in vitro dermal absorption methods (as discussed under Section III.B).*

**HHAB Response:** It is HHAB practice to use chemical-specific data when available and surrogate data or default values when high quality chemical-specific data are not available. Although the *in vitro* dermal absorption studies submitted by the registrant for dicrotophos were not ideal, they were appropriate enough for estimating dermal absorption.

**Statement 9:** *“Worker exposure estimates were based on PHED surrogate data and do not consider newer available data.”*

**OEHHA Response:** *As described in Section I, Summary of Review, OEHHA agrees that exposure estimates derived using PHED-based surrogate data for occupational handlers are reasonable. However, OEHHA is concerned with the continued reliance on PHED and suggests that DPR should begin supplementing PHED data with data from other sources whenever possible. OEHHA also recommends that DPR include or cite the specific PHED scenarios, data and calculations used to generate these exposure estimates to increase the transparency of the draft EAD.*

**HHAB Response:** AHETF provided DPR with the worker exposure database, which HHAB is in the process of reviewing for use as surrogate handler exposure estimates when chemical-specific data are unavailable. Once the data evaluation is completed, the dicrotophos EAD will be updated based on AHETF data. The uncertainties attributed to PHED data for developing exposure estimates will be considered during the mitigation phase.

**Statement 10:** *“Aerial concentrations of dicrotophos from groundboom applications cannot be estimated due to limitations in the AgDRIFT model.”*

**OEHHA Response:** *OEHHA concurs with DPR that the AgDRIFT model cannot be used to estimate air concentrations resulting from groundboom applications. AgDRIFT uses deposition curves derived for ground applications based on measured values that bounded 50% or 90% of the data at each point. Since there is currently no other US EPA-approved method or model for estimating air concentrations near groundboom applications, OEHHA agrees that bystander aggregate exposure near groundboom-treated fields will likely be underestimated as the current DPR approach does not account for inhalation of spray drift or post-application volatilization (as discussed under Section III.G.2).*

**HHAB Response:** The comment by OEHHA on the limitation of the AgDRIFT model is noted.

### **II.C. Risk Characterization**

**Statement 11:** *“DPR RAS used 10% brain ChEI in rats as the critical toxicity endpoint for short-term and steady-state exposure to dicrotophos for all scenarios. Therefore, the target MOE was 100 assuming humans are 10-fold more sensitive than rats and there is a 10-fold variation in the sensitivity of the human population.”*

**OEHHA Response:** *OEHHA generally recommends the use of a UF of 10 for interspecies extrapolation and a UF of 30 for intraspecies variability. OEHHA suggests a total UF of 300 for the general adult population. In the case of dicrotophos, OEHHA also supports an additional UF of 10 to protect against DNT because of the reported changes in brain weight and morphometry in pups exposed in utero (Brammer, 2003). If an additional 10-fold UF is applied to protect against DNT in the sensitive population, this would offer additional protection against both pharmacokinetic and pharmacodynamic variability in fetuses, infants and children, and the intraspecies UF could be reduced to 10 rather than 30. This would then result in a total UF of 1000 for the sensitive population. This is consistent with the approach taken by US EPA (2015a) in its recent assessment of dicrotophos. See detailed discussion under Sections III.D and III.E.*

**HHAB Response:** HHAB recommends using a total UF of 1000 for sensitive population subgroups which is consistent with U.S. EPA’s 2015 risk assessment for dicrotophos.

**Statement 12:** *“DPR RAS is considering the use of an additional uncertainty factor of 10 with dicrotophos to protect infants, children and women of child-bearing (age) from potential neurodevelopmental toxicity by non-ChEI mechanisms (US EPA, 2015b).”*

**OEHHA Response:** *As stated above, OEHHA recommends DPR apply an additional 10-fold UF to protect the sensitive population. This is supported by the findings of brain weight and morphometry changes in a DNT study of dicotophos (Brammer, 2003) and consistent with US EPA's recommendation in the "Literature Review on Neurodevelopment Effects & FQPA Safety Factor Determination for the Organophosphate Pesticides" (US EPA, 2015b). See detailed discussion under Sections III.D and F.*

**HHAB Response:** HHAB is recommending using an additional 10X UF to protect infants, children, and women of childbearing age from possible neurodevelopmental effects through non-ChEI mechanisms based on U.S. EPA's systematic review of the literature.

### **III. DETAILED COMMENTS**

#### **III.A. Introduction**

##### **III.A.1. Physical and Chemical Properties, and Environmental Fate**

*Dicotophos is highly water soluble, but is also soluble in some less polar solvents such as xylene. The draft SLN review does not mention that BIDRIN®8 is a mixture of two isomers with 85% in the form of the pesticidally-active E-isomer (US EPA, 2006). OEHHA recommends that DPR include additional information about the chemical and physical properties of dicotophos, emphasizing its high water solubility and the bioactivity of the E-isomer.*

*No fate and transport information was provided in the draft RCD or draft EAD. Considerable data on dicotophos stability, mobility and degradation exist and should have been included in this draft EAD. OEHHA recommends that DPR include additional information about dicotophos such as its stability in water and soil, mobility in soil, and volatilization potential.*

**HHAB Response:** This information was originally omitted because the dicotophos EAD was intended to be a condensed exposure assessment and label review for 24(c) Special Local Need registration. Additional physiochemical properties and information on environmental fate has now been added to the EAD.

##### **III.A.2. Pesticide Use and Sales**

*Under the proposed SLN Registration (24C) for dicotophos use on cotton, a maximum application rate of 1 pound/acre/season is allowed during the "growth period" between first bloom and 30 days before harvest. The early stages of bloom development are considered the most susceptible period for stink bug damage (VCE, 2009). A recent survey of dicotophos use on cotton in the southern United States reported 1-2 applications per season (US EPA, 2014c), however the registrant states that it is not uncommon "to make four to six total insecticide applications due to stink bug migration into cotton" (AMVAC, 2014). OEHHA recommends that the draft EAD provide additional California-specific details about anticipated frequencies of aerial and ground application, as well as the anticipated seasonal use and timing of application.*



**HHAB Response:** According to the label, the “growth period” between first bloom and the 30 day pre-harvest interval (PHI) corresponds to the seasonal exposure period. If the cotton plants bloom at 8-10 weeks after planting and the plants are harvested at 25 weeks (CottonJourney.com, 2015), then the “growth period” or exposure season for dicotophos application is 11-13 weeks or approximately 3 months after planting. The EAD initially assumed a 1-2 month “season”, which has since been changed to reflect a 3 month “season”. This change in the length of the season did not alter the estimates for seasonal exposure because HHAB assumes a maximum application rate of 0.5 lb AI/acre. Data are not available to justify a lower application rate “typical” for seasonal use of dicotophos. Additionally, total applications per year are restricted to 1 lb AI/acre, leaving the maximum number of applications per season at two.

### **III.A.3. Reported Illness**

*Dicotophos has not been registered for use in California since 1991. For that reason, no cases of dicotophos-related illness in agricultural workers have been reported in the state since that time. However, the National Institute of Occupational Safety and Health Sentinel Event Notification System for Occupational Risks (NIOSH SENSOR) program identified 26 cases of dicotophos-related illness from 1999 to 2008 in other states (US EPA, 2012b). Ten of the 26 cases were exposed in a residential setting, with 9 of the 10 residential cases classified as bystander exposures resulting from spray drift from aerial applications of cotton. OEHHA recommends that the draft EAD discuss the NIOSH SENSOR data as it appears to validate DPR and OEHHA’s concern for the bystander spray drift exposure scenario.*

**HHAB Response:** The illness section of the EAD has been updated as suggested by OEHHA.

### **III.B. Pharmacokinetics**

*The absorption, distribution, metabolism, and excretion of dicotophos are relatively simple and adequately addressed in the draft RCD. Dicotophos causes ChEI, an effect that does not require metabolic activation. Dicotophos is also rapidly absorbed and extensively metabolized. While most of the metabolites are readily excreted, 3% is metabolized to monocotophos, which has similar ChEI activity as the parent compound. Oral absorption efficiency was 94-97%. There were no studies on inhalation absorption so a default absorption rate of 100% was used. OEHHA agrees with this approach.*

*A dermal absorption factor to estimate systemic dose via dermal exposure was calculated using a new methodology based on in vitro and in vivo data. One registrant study provided in vivo rat data (Gledhill, 1999) and another evaluated both human and rat in vitro dermal absorption (Davies, 1999). In an appendix and supporting memorandum to the draft RCD, DPR described a procedure using data from these studies to calculate a 95% upper confidence level (UCL) of 26.3% that was used as the human dermal absorption rate (DPR, 2015b; DPR 2015c).*

*OEHHA is concerned about the quality of the in vitro rat and human studies and agrees with comments provided in the supporting memorandum, describing numerous shortcomings of the Davies study such as missing data points as well as a lack of procedural and technical details (DPR, 2015c). However, the memorandum did not mention whether the study also reported skin*

*source, skin integrity or the presence of solvents and/or co-formulants. In evaluating these studies, OEHHA recommends that the draft EAD discuss how the in vitro study design differs from OECD guidelines as well as any major confounding factors.*

**HHAB Response:** Discussion of the *in vitro* study has been expanded in the revised EAD.

*OEHHA is also concerned with the number and quality of references provided in the draft EAD. A two-page document, "NAFTA Dermal Absorption Group Position Paper on Use of In Vitro Dermal Absorption Data in Risk Assessment," was cited in Charge Statement #8 to support the approach that DPR used to analyze the available dermal absorption data for dicrotophos. The members of this working group were not identified, the document was unpublished and apparently not peer reviewed, and its release date was not indicated. In our opinion, these deficiencies undermine the utility of the NAFTA document for the exposure assessment and it should not be used.*

**HHAB Response:** OEHHA's comment on the North American Free Trade Agreement (NAFTA) document NAFTA TWA, 2012 is noted. However, in the absence of other references, this document is retained to support the use of the triple-pack method that is currently being developed by U.S. EPA, PMRA, and Mexico. Additional references have been added to the EAD documenting the use of the triple-pack method by both U.S. EPA (2008, 2010, 2013) and PMRA (2011, 2015), two of the main developers of this approach.

*OEHHA is concerned that a complex mathematical analysis was used to estimate the dermal absorption of dicrotophos in humans (DPR, 2015b; DPR 2015c). The analysis relied heavily on the results of the in vitro and in vivo dermal absorption of dicrotophos in rats – a species that often over-predicts transdermal absorption of chemicals in humans. Therefore, OEHHA recommends that DPR use data from a dermal exposure study of monocrotophos in humans (Feldmann and Maibach, 1974) to calculate an upper end estimate of the dermal absorption of dicrotophos.*

*This recommendation is based on the following considerations: (1) dicrotophos and monocrotophos have comparable molecular structures, differing from one another by a single methyl group; (2) both compounds have very similar values for water solubility and KOW - parameters that are critical determinants of transdermal absorption; (3) the experimental subjects in the study were humans, so interspecies extrapolation is not required; (4) the site of skin application in the study (ventral forearm) is highly relevant to the anticipated site of exposure that pesticide handlers and cotton scouts are expected to experience; and (5) the authors of this report also determined the amount of test compound excreted in the urine following intravenous administration (100% absorption) to correct incomplete urinary excretion (Feldmann and Maibach, 1974).*

*Feldmann and Maibach (1974) reported that the dermal absorption of monocrotophos in six human subjects was  $14.7 \pm 7.1$  (mean  $\pm$  SD) percent. Assuming these data are normally distributed, the 95th percentile estimate from the Feldmann data is 26% (calculated with the NORMINV function in Excel®). These results are consistent with the results of DPR's analysis*

*that produced a 95% upper confidence limit of 26.3%, and they provide a more transparent basis for estimating dermal exposure to the pesticide in humans.*

**HHAB Response:** The “triple-pack” approach is a two-step process where the first step is to determine the difference in absorption measured by an *in vitro* test compared to that measured by an *in vivo* test for the same compound of interest. In essence, the first step is to gauge how well the *in vitro* methodology predicts the *in vivo* dermal absorption methodology. If the animal ratio overlaps the value of one, it may be concluded then that the *in vitro* test conditions are appropriate enough to reproduce *in vivo* test results. In the second step, the errors associated with the animal tests are incorporated with the errors from the *in vitro* human test to estimate a human absorption value. From this perspective, the animal data is only being used to validate the human *in vitro* data, and the interspecies difference in absorption is preserved.

For the 24 hr time point and 1:1000 dilution, the mean *in vitro* rat absorption was 53.9% while the mean *in vivo* rat absorption of dicotophos was 43.7%. The 95<sup>th</sup> percentile confidence interval on the ratio of the *in vitro* to *in vivo* animal data would give a percent absorption of  $1.23 \pm 0.35$ . This ratio meets the criterion of overlapping the value of one. Using the technique of error propagation, the error associated with this animal ratio is incorporated into the 95<sup>th</sup> percentile confidence interval calculated for the mean human *in vitro* absorption value (at the same time and concentration as the animal data) to give a percent absorption of  $19 \pm 11.7$ . Taking the conservative upper bound of this range gives the estimated value of 26.3%, which is approximately half that observed in the rat experiments. This dermal absorption estimate is based on actual human data. Though corroborated by animal data, the known over-estimation of one species, rat, in this case, does not dominate the predicted value.

### **III.C. Non-cancer Toxicity Endpoint and Dose-Response Analysis**

*No human toxicity studies were described in the draft RCD, and DPR chose to evaluate brain ChEI from laboratory animal studies for deriving PODs for dicotophos for acute and steady state exposure durations. OEHHA agrees with this general approach, with the exception for the DNT study (Brammer, 2003). A variety of clinical signs of neurotoxicity were also observed in the animal studies but mostly occurred at higher doses than the dose for ChEI. Furthermore, brain ChEI data in the animal studies are extensive and allow for comparison across multiple life stages, as well as exposure routes and durations.*

*Compared to previous RCDs, this draft RCD included only a brief hazard identification section highlighting the lowest- and no-observable effect levels (LOEL/NOELs) and BMD/BMDLs from available studies. Because of the limited scope of this draft RCD (SLN use on cotton only) and the decision to only evaluate brain ChEI as the critical endpoint, a complete toxicological profile was not provided. OEHHA agrees with this approach but suggests providing more details on the critical studies.*

*In agreement with the approach used in this draft RCD, OEHHA advocates the use of the BMD modelling over the LOEL/NOEL approach. Brain ChEI in the animal studies for dicotophos generally showed good dose-response relationship with sufficient number of animals to permit*

*BMD modeling. One of the major differences in the BMD analyses done by DPR and that done by US EPA for the risk assessment of dicrotophos (US EPA, 2015a) was the inclusion of the Hill model in addition to the exponential models, the only model type used by US EPA for ChEI data. OEHHA agrees with DPR in including the Hill model in the BMD analyses and not relying only on exponential models. Our opinion is that we should select the model that most accurately describes the data. In many cases in the draft RCD, the Hill model provided a substantially better fit (higher Test 4 p values) and thus should be included.*

*In the DPR's BMD analyses for the POD selection, there were instances where one or more of the tests had non-significant p values yet the information was not provided in the draft RCD. For transparency, OEHHA suggests DPR include the selected models for each study/endpoint and the model output results, such as p values, Akaike information criteria (AICs), and scaled residuals. For endpoints that failed one or more of the tests, OEHHA also suggests that the BMD/BMDL values should be included in the summary tables (Tables 3-5 in the draft RCD) for comparison purposes. However, only those models with significant p values that meet all the criteria for model selection should be selected for PODs. Reasons for selecting a specific model over others should also be provided in the draft RCD. Complete BMD model outputs for the critical endpoints may also be included in the appendices.*

**HHAB Response:** Detailed descriptions of the critical studies, including the developmental neurotoxicity study, were added to the Neurotoxicity and Carcinogenicity sections. In addition, Appendix III has been added to the RCD with the results from the BMD batch runs for each data set. The output includes the p-values for Tests 1-4, AIC, scaled residuals, BMD and BMDL values. A footnote was provided under each batch run to explain what criteria was used to select the model highlighted or why a model was not selected.

### **III.C.1. Acute Oral Exposure**

*For acute oral exposure, DPR chose a BMDL10 of 0.03 mg/kg-day for brain ChEI in PND8 male rats as the acute oral POD (Moxon, 2003a). In this acute ChEI study, pre-weaning rats at PND8, 15 and 22 (5 pups/sex) were dosed with 0, 0.1, 0.3, 1 and 5 mg/kg dicrotophos by gavage and assessed for brain and red blood cell ChEI 2 hours after dosing. There was no clear NOEL for this study. PND8 males, PND15 males and females, and PND22 females all had ChEI even at the lowest dose (i.e., indicating a NOEL of <0.1 mg/kg-day). BMD analysis of brain ChEI data resulted in a range of BMDL10s of 0.03 (PND8) to 0.13 (PND22) mg/kg-day. The Hill model for male PND8 brain ChEI had the lowest BMDL10 from the acute/short-term database (0.03 mg/kg-day), provided good model fit and met all the criteria for BMD model selection. Applying a UF of 3 to extrapolate from the lowest LOEL of 0.1 mg/kg-day to NOEL would also result in an estimated POD of 0.03 mg/kg-day, adding confidence to the BMDL10 determination. DPR applied the acute oral POD of 0.03 mg/kg-day to both the general adult population and sensitive population. OEHHA agrees with the application of this POD.*

**HHAB Response:** No response needed.

### **III.C.2. Steady-State Oral Exposure**

DPR selected a BMDL<sub>10</sub> of 0.025 mg/kg-day for brain ChEI from a subchronic neurotoxicity study in adult female rats as the steady-state oral POD (Horner, 1995). In this 90-day neurotoxicity study, adult Alpk:APfSD rats (12/sex/dose) were fed 0, 0.5, 5 or 25 ppm dicrotophos in the diet for 13 weeks and assessed for ChEI, functional observation battery (FOB) and motor activity. Satellite groups of 6 animals/sex/dose were also assayed at 5 and 9 weeks for the same endpoints. Average doses were calculated as 0, 0.04, 0.39, and 2.03 mg/kg-day for males and 0, 0.04, 0.45, and 23.8 mg/kg-day for females. There were significant reductions in brain ChEI at all doses tested. The consistency in BMDL<sub>10</sub> values in females measured after 5, 9 and 131 weeks of exposure demonstrates ChEI had reached a steady-state at 5 weeks. The BMDL<sub>10</sub>s for males in the study are slightly higher but ChEI also reached a steady-state following 5 or more weeks of treatment. The NOEL from the study was <0.04 mg/kg-day. BMD analyses of brain ChEI resulted in BMDL<sub>10</sub>s of 0.025 for females and 0.031-0.036 for males. The draft RCD chose 0.025 mg/kg-day as the POD for steady-state oral exposure. It should be noted there is a study with bolus dosing which indicates lower BMDLs (0.005 mg/kg-day for females and 0.015 mg/kg-day for males) than the POD selected. In this study, 10 adult rats/sex/group were dosed with 0, 0.008, 0.02 or 0.4 mg/kg-day dicrotophos by gavage for 28 days (Brammer, 2002). NOELs from this study based on brain ChEI were 0.02 and 0.008 mg/kg-day for males and females, respectively. Corresponding BMDL<sub>10</sub>s were 0.015 (males) and 0.008 mg/kg-day (females). While these were lower than the BMDLs from Horner (1995), DPR did not select the POD from this study because of the concern on the route of administration. OEHHA agrees that bolus dosing resulting from gavage administration could cause greater ChEI than occurring from dietary or drinking water exposure, and that a dietary study would better represent the human exposures evaluated in the draft EAD.

**HHAB Response:** No response needed.

### **III.C.3. Inhalation Exposure**

There was one inhalation toxicity study for dicrotophos in the database appropriate for risk assessment. In this study, 10 CrI:CD rats/sex/group were exposed to 0, 0.097, 0.73 or 2.9 µg/L dicrotophos by nose only inhalation for 6 hours/day, 5 days per week for 4 weeks (Blair, 2010). Brain ChEI was the most notable adverse effect and was significant at all doses in females and at 0.73 and 2.9 µg/L in males. Other effects included a decrease in mean reticulocytes and atrophy of the seminiferous tubules in males at 2.9 µg/L. DPR chose an average BMDL<sub>10</sub> of 0.42 µg/L from the male and female datasets as the POD to evaluate inhalation exposure for workers and bystanders for all exposure durations (Blair, 2010).

OEHHA has concerns regarding the BMD model selection and recommends additional discussion on the differences between NOEL/BMDL and justification for choosing a higher POD. As shown in the following table (Table 1) using information from Table 4 of the draft RCD, the NOELs for the study were 0.097 µg/L for males and <0.097 µg/L for females. The lack of a NOEL for females was due to a statistically significant reduction of brain ChE in females at the lowest dose tested.

*While the biological significance of a 7% reduction in ChEI is unclear, the calculated BMDL10 of 0.41 µg/L for females was over 4 times higher than the LOEL for females (0.097 µg/L). The BMD model selected for females also failed tests 3 and 42 in BMD analysis and the result is not recommended for use based on BMD model selection criteria. The BMDL10 of 0.43 µg/L for the male rat was also over four times higher than the NOEL for males (0.097 µg/L). And the model selected for males also failed test 3 in BMD modeling. When modeled without constant variance, both the exponential M2 and M3 models have significant p values for all tests and the BMDL10 is 0.652 µg/L, over 6 times higher than the NOEL for males. For this dataset, the NOEL/LOEL approach is appropriate. OEHHA recommends applying an UF factor of 3 to extrapolate from LOEL to NOEL, resulting in an estimated NOEL of 0.032 µg/L for females from the Blair (2010) study. Because inhalation is a major route of exposure and this is the only inhalation study to consider, additional discussion of these differences in PODs and consideration of a lower POD is warranted.*

*The same subchronic inhalation toxicity study and POD was used to evaluate both short-term and seasonal inhalation exposure. For dicrotophos, OEHHA agrees that an acute exposure by the same route would likely result in a higher NOEL or POD (as is the case for oral toxicity studies) and thus using a subchronic POD to evaluate acute exposure is health-protective. DPR assumed 100% absorption of dicrotophos by the inhalation route and a default rat breathing rate of 40 liters per hour (L/hr). In the absence of data to indicate otherwise, OEHHA agrees with the default absorption rate. The default rat inhalation rate of 40 liters per kilogram body weight-hour (L/kg-hr) is consistent with the inhalation rate calculated by US EPA for dicrotophos (43.5 L/kg-hr; US EPA, 2015a) and OEHHA's Technical Support Document for the Derivation of Noncancer Reference Exposure Levels (2008, Appendix F: p. 2; minute volume of 0.180 L/min calculated for 0.25 kg rat using parameters provided corresponds to 43 L/kg-hr). The slightly lower breathing rate calculated by DPR is likely due to a slightly different default rat body weight applied in the calculation.*

**HHAB Response:** In the traditional NOEL/LOEL approach, the threshold dose is dependent on the dose selection in the study. HHAB contends that the BMDL approach is particularly useful when a NOEL is not observed. It is also useful when the dose levels are widely spaced apart. Both of these situations apply in this risk assessment. An apparent NOEL was not observed in the females and the difference in the low dose (0.097 µg/L) and the mid dose (0.73 µg/L) is 7.5-fold. With regard to the BMD analysis performed, HHAB followed U.S. EPA's approach for identifying a threshold for brain ChEI which was to set the BMR at 10% relative deviation. This is consistent with what U.S. EPA did for the cumulative risk assessment for organophosphate pesticides. This BMR is above the level of inhibition that was statistically significant in females by pairwise comparison with controls. It should be noted that the mean brain ChE activity seen in males and females was similar at the same treatment levels, but noticeably different in the control groups (Males: 2.33, 2.33, 2.07, 1.52 U/g; Females: 2.44, 2.28 2.07 and 1.51 U/g). Therefore, the significant brain ChEI in females at 0.097 µg/L may be an artifact due to an unusually high activity in control females. The results from HHAB's BMD analysis were not ideal in that both males and females had non-homogenous variances which has a resulting test 3 p-value less than 0.1 and greater than 0.05. With males, the test 3 p = 0.098 and the test 4 p-values for the Exponential Models 2 and 4 were well over 0.10, so the output for these models

are considered acceptable. Model 4 had the best fit based on the largest test 4 p-value. Model 2 had a lower AIC due to being a simpler model, but greater weight was given to the model fit (test 4 p-value). Model 4 also resulted in a more health protective BMD and BMDL. For females, the test 3 p-value is closer to 0.05 and the test 4 p-values are significantly less than 0.1, so the output from this BMD analysis is more questionable. Originally HHAB used the BMD and BMDL for females from the Hill model and averaged it with the males since it was so similar. But in reevaluating the test 4 p-values, we decided to use only the BMD and BMDL estimates for the males. Since the mean values in the female treatment groups was not that different from the males, we consider the BMDL for the males to be protective of the females as well.

### **III.C.4. Dermal Exposure**

*There was only one dermal toxicity study which measured brain ChEI and was appropriate for assessing acute and steady-state dermal exposure. In Noakes (2001), the skin of 15 Crl:CD rats/sex/dose were treated with 0, 2, 5, 10 or 80 mg/kg-day dicrotophos for 6 hours/day, 5 days/week for 4 weeks. ChEI (brain, plasma, and RBC) was the only treatment-related effect other than erythema in females. The subchronic dermal NOEL from the study was 5 mg/kg-day in both males and females. Calculated BMDL10s for brain ChEI were 3.50 mg/kg-day for males and 2.13 mg/kg-day for females.*

*OEHHA agrees with the selection of Noakes, 2001 as the critical study to evaluate dermal exposure to dicrotophos. Because females had a lower BMDL<sub>10</sub>, significant p value for Test 4, and a better visual fit of the data, OEHHA agrees with the selection of the BMDL<sub>10</sub> of 2.1 mg/kg-day as the critical POD. Note that the p value for males is not significant for Test 4 (model fit) and for females is not significant for Test 3 (model variance). This should be indicated in the summary table (Table 5 from the draft RCD) or in a separate table summarizing the outputs for the chosen models. Similar to the case for inhalation exposure, OEHHA agrees with the use of a POD from a subchronic dermal toxicity for acute dermal exposure.*

**HHAB Response:** The p-value for Test 3 is shown in the model output in Appendix III summarizing the BMD analysis.

### **III.D. Reproductive and Developmental Toxicity**

*Dicrotophos was tested for reproductive toxicity in a multi-generation study in rats. Moxon (1997) treated 26 Wistar rats/sex/group (F0 generation) with 0, 0.5, 5.0 or 25 ppm in the diet from 10 weeks before mating until 4 weeks of lactation. There was high mortality in the offspring from the high dose group in the F1 generation, so the high dose was reduced to 10 ppm. The parental generations mainly had effects on body weights and clinical signs of toxicity at 25/10 and 5 ppm. There was reduced pup viability at 5 ppm in both F1 and F2 generations. Both the parental and the developmental NOELs were 0.5 ppm for the study, which equated to approximately 0.05 mg/kg-day. While these are higher than the PODs chosen for the steady-state oral exposure, the toxicity data from this study demonstrate there is a concern for toxicity in young animals at low doses not mediated through the ChEI mechanism.*

*There are two developmental toxicity studies for dicrotophos, one in Sprague-Dawley rats (Rodwell, 1986) and one in New Zealand White rabbits (Moxon, 2001). In the first study, 25 mated female Sprague-Dawley rats/sex/group were treated with 0, 0.1, 0.5, 1.0 or 2.0 mg/kg-day dicrotophos by gavage from gestational day (GD) 6 to GD15. In the other study, 28 mated female New Zealand White rabbits were treated with 0, 0.5, 1.0, or 2.0 mg/kg-day dicrotophos by gavage from GD5 to GD29. Body weights, clinical signs, and litter outcomes were measured in each species. In both studies, developmental NOELs (2.0 and 1.0 mg/kg-day for rats and rabbits, respectively) were higher than maternal NOELs (0.5 mg/kg-day for both species) and developmental toxicity was not indicated in the rat study.*

*There is one DNT animal study in the dicrotophos database. Brammer (2003) dosed 30 time-mated female Wistar rats per group with 0, 0.01, 0.05, and 0.4 mg/kg-day of dicrotophos by gavage from GD7 to postpartum day 7. Pups were also dosed from PND8 to PND22. Neurotoxicity was assessed by FOB, motor activity measurements, and brain histopathology. There were no significant effects on Functional Observational Battery (FOB) or motor activity in male and female offspring. However, there were statistically significant increases in absolute brain weights of female pups at 12 days after birth at all dose groups tested. Brain weights were also assessed by analysis of covariance on final body weight by study authors. When adjusted for final body weight, brain weights were statistically increased at the highest dose, 0.4 mg/kg-day. This statistical approach is consistent with recommendations in the open literature for optimum organ weight analyses (Bailey et al., 2004).*

*There were also statistically significant changes in various brain morphometric measurements at 0.4 mg/kg-day, the only treated group examined, when the brains were examined on PND 12 and 63. At day 12, male pup brains exhibited significantly decreased frontal cortex height and width, while female pup brains had significantly decreased thickness of the dorsal cortex and increases in multiple measurements of the hippocampus. At day 63, male brains had decreased thalamus/cortex overall width while female brains only had decreased width of the thalamus. Females also had decreased hypothalamus length from the midline.*

*In the draft RCD, this study was presented only by the NOEL of 0.4 mg/kg-day and a notation of "No adverse effects" in Table 4 (page 10; DPR, 2015d). DPR stated in their Summary of Toxicological Data for dicrotophos (DPR, 2015d) that there were no consistent effects on brain structure and established the maternal and developmental NOELs at the highest dose tested (0.4 mg/kg-day). On the other hand, US EPA established a developmental No-Observed-Adverse-Effect Level (LOAEL) of 0.05 mg/kg-day for changes noted in the brain at 0.4 mg/kg-day (US EPA, 2015a).*

*OEHHA believes that the effects on the brain are important and they were not adequately analyzed in the draft RCD. The brains of PND12 female rats showed the most significant changes and their results are summarized in Table 2. Absolute brain weight is statistically significant for PND12 females at 0.01 mg/kg-day. The absolute brain weight data were not amenable to BMD modeling. Based on statistical significance of increased absolute brain weight in females at the lowest dose tested, there was no clear NOEL from the study. OEHHA's practice is to apply a UF of up to 10-fold to extrapolate from LOEL to NOEL. In this case a factor of 3 seemed sufficient since the dose-response relationship is shallow with only a 2-fold increase (105% to 109% of control) over a 40-fold dose range (from 0.01 to 0.4 mg/kg-day).*



*Furthermore, while increases in brain weight resulting from in utero exposures to dicrotophos are concerning, the toxicological significance at this magnitude of change is unclear. Applying a 3-fold UF factor would result in an estimated NOEL of 0.003 mg/kg-day for this endpoint. OEHHA suggests that DPR re-examine the results of this study in determining the oral POD for the sensitive population and in considering the need for an additional UF to protect against DNT (see Section III.F.2.c).*

**HHAB Response:** As mentioned previously, this RCD was intended to be an expedited risk assessment given that it was for a 24c registration and registration was dependent on the findings of this assessment. To expedite the process, individual studies were not reevaluated unless there was an endpoint of concern was flagged in the Toxicology Summary. In the initial review of this study by the DPR Data Review Section (DRS), the increase in absolute brain weights was not considered toxicologically significant because the relative brain weights did not increase. Furthermore, HHAB generally does not consider organ weight changes alone to be toxicologically significant in the absence of any related histopathological findings or clinical signs. There were no treatment related increases in neurobehavioral signs or histopathological findings in the brains of pups in this study. The changes in morphometric measurements (which were only measured in controls and high dose group) were not considered treatment related because there was no consistent region affected or direction of change (increased or decreased) between sexes on days 12 or 63. Therefore, the NOEL was set at the high dose by the study reviewer. After reevaluating these data and the reference cited by OEHHA (Bailey et al., 2004), HHAB agrees that a more detailed discussion of the developmental neurotoxicity study is needed in the RCD. In addition, and out of an abundance of caution, HHA is lowering the NOEL to 0.05 mg/kg/day based on the statistically increase in brain weights at 0.4 mg/kg/day based on an analysis of covariance with body weight at the covariate. However, it should be noted that this NOEL is still higher than the BMDL<sub>10</sub> of 0.03 mg/kg/day for brain ChEI in PND8 pups, an endpoint that is more widely recognized for adversity. HHAB does not agree with using the absolute brain weight as an endpoint for setting a NOEL based on the comment by Bailey et al. (2004) that absolute organ weight is never the optimal endpoint for evaluating organ weight changes in the presence of body weight differences between groups. While not statistically different, there was an increasing trend in terminal body weights. This is why the relative brain weights did not show an increase, and actually tended to decrease as the dose increased.

### **III.E. Carcinogenicity Weight of Evidence**

#### **III.E.1. Genotoxicity**

*Dicrotophos was positive for mutagenicity in a mouse lymphoma forward mutation assay with and without metabolic activation (San and Clark, 1995). Dicrotophos was negative in other guideline genotoxicity assays. However, positive results were reported by Wu et al. (2010) for chromosome aberrations in CHO-K1 cells and DNA damage in comet assay for HEPG2 cells. Also, structurally similar monocrotophos, a metabolite of dicrotophos, showed positive genotoxicity evidence (DPR, 2015d). In the draft RCD, DPR stated there is “no strong evidence of genotoxicity.” While the registrant submitted studies were only weakly indicative of*

*genotoxicity, the study by Wu et al. (2010) demonstrated the genotoxic potential of dicrotophos. OEHHA suggests DPR include an evaluation Wu et al. (2010), and any other relevant open literature studies for a more thorough evaluation and a greater concern for the genotoxicity potential of dicrotophos.*

**HHAB Response:** Please see response on page 5 of this document.

### **III.E.2. Human and Experimental Animal Evidence**

*There are no human data on the carcinogenic potential of dicrotophos. DPR reviewed two chronic laboratory animal studies in two species for evidence of carcinogenicity of dicrotophos. There was no evidence of tumors in rats (Fifty two Alpk:APfSD rats/sex/dose) fed 0, 0.5, 5.0, or 25 ppm dicrotophos in the diet for 2 years (Allen, 1998). There was, however, a dose-related increase in follicular cell adenomas of the thyroid gland (Table 3) in a study with mice (55 C57BL/10JfCD-1 Alpk mice/sex/dose) fed dicrotophos in their diet at 0, 5, 10 or 50 ppm, for 105 weeks (Milburn, 1998). The doses were equivalent to 0, 0.02, 0.25 and 1.42 mg/kg-day for males and 0, 0.03, 0.32, and 1.74 mg/kg-day for females. The increase of the follicular cell adenomas in male mice was statistically significant by trend analysis ( $p < 0.01$ ) and by pairwise comparison ( $p < 0.05$ ). These tumors were found at the study termination (105 weeks). Male mice also had a minimal increase in follicular epithelial hyperplasia of the thyroid gland at the high dose. Two of the high dose males had both hyperplasia and adenoma. Historical control incidence of thyroid adenoma was low (range from 0% to 3.4% from 1984 to 1996). This study did not measure thyroid hormone levels and provided no information on the mode of action. Female mice in this study did not show a significant increase in these tumors or any other tumors, but they did have a reduced survival rate which could have affected the results. Females had a dose dependent increase in mortality after 1 year, with the high dose group having the greatest early mortality. Mortality in the males was unaffected by dicrotophos treatment but was in excess of 40% for all dose groups, including the controls. There is no evidence of thyroid effects in the database.*

**HHAB Response:** No response needed.

### **III.E.3. Other Evidence**

*Dicrotophos is structurally similar to monocrotophos, another OP insecticide. DPR reviewed the oncogenicity studies of monocrotophos and found no evidence of tumors in mouse or rat bioassays. There was minimal positive genotoxicity evidence (positive reverse mutation assay, forward mutation assay as well as few in vitro assays for DNA damage) but none met US EPA's current guidelines for genotoxicity assays.*

*DPR also reviewed ToxCast™ data for dicrotophos in the draft RCD. There were positive assays suggesting some upregulated inflammatory responses, effects on one of the cytochromes (Cyp2C19), human butylcholinesterase, and an estrogen response element. While the inflammatory responses and effects on Cyp2C19 could be involved in the increased incidence of thyroid tumors, DPR concluded that the limited evidence did not support determining dicrotophos as a carcinogen. OEHHA concurs with DPR on this determination.*

**HHAB Response:** No response needed.

#### **III.E.4. Potency Determination Approach**

OEHHA agrees with DPR that there is insufficient *in vivo* evidence to derive a cancer potency.

**HHAB Response:** No response needed.

#### **III.F. Extrapolation, Variability, and Uncertainty**

##### **III.F.1. Duration Extrapolation**

*For the oral exposure scenario, no extrapolation for length of exposure was necessary. DPR chose a POD from an acute oral toxicity study (Moxon, 2003a) and no extrapolations for length of exposure were necessary. For steady-state oral exposure, DPR selected a POD from a 90-day dietary (subchronic) study. The selected BMDL10 of 0.025 mg/kg/day was the same BMDL10 calculated for females at 5, 9 and 14 weeks in the study, suggesting that ChEI reaches steady-state following subchronic exposure.*

*As previously discussed, for inhalation and dermal exposure scenarios, POD from the respective route subchronic toxicity studies were used to evaluate both acute and steady-state exposures for bystanders and short-term and seasonal exposure for workers/handlers. For dicrotophos, OEHHA agrees that an acute exposure by the same route would likely result in a higher NOEL or POD and thus using a subchronic POD to evaluate acute exposure is health-protective.*

**HHAB Response:** No response needed.

##### **III.F.2. Uncertainty Factors**

###### **III.F.2.a. Interspecies Extrapolation**

*OEHHA supports DPR's use of an interspecies UF of 10 because all PODs were derived from laboratory animal studies.*

**HHAB Response:** No response needed.

###### **III.F.2.b. Intraspecies Extrapolation**

*In the draft RCD, an intraspecies UF of 10-fold was applied to account for pharmacokinetic and pharmacodynamics differences within the human population. OEHHA recommends that this factor be increased to 30 (total of 10 for pharmacokinetics and  $\sqrt{10}$  for pharmacodynamics). For non-cancer effects, OEHHA's view is that there are many factors affecting human variability in response to a chemical exposure (OEHHA, 2008; Zeise et al. 2013). Thus, based on analyses of human pharmacokinetic variability, OEHHA's practice is to increase the traditional*

*intraspecies pharmacokinetic UF of  $\sqrt{10}$  to 10 (OEHHA, 2008). This increase would account for the wide variability in pharmacokinetics in the population, especially among subpopulations such as infants and children, pregnant women, and the elderly. However, if an additional 10-fold UF is applied to protect against DNT in the sensitive population, this additional UF would offer additional protection against both pharmacokinetic and pharmacodynamic variability in fetuses, infants and children. Thus, in this case, a total intraspecies UF of 10 for intraspecies pharmacodynamic and pharmacokinetic variability, in combination with the additional UF of 10 for DNT, would be sufficient.*

**HHAB Response:** In the case of dicrotophos, we assumed a default intraspecies factor of 10 that includes a pharmacokinetic UF of  $\sqrt{10}$  and a pharmacodynamic UF of  $\sqrt{10}$ . We are also recommending an additional 10X UF to protect infants, children, and women of childbearing age against possible neurodevelopmental effects through non-ChEI mechanism based on U.S. EPA's systematic review of the literature. Therefore, the total recommended UF for sensitive subpopulations is 1000. This is in agreement with U.S. EPA in their 2015 health assessment for dicrotophos.

### **III.F.2.c. Additional Uncertainty Factor**

*Dicrotophos is a known neurotoxicant and can potentially cause developmental neurobehavioral effects. The DNT animal study by Brammer (2003) showed significant effects in the brain of female pups at the lowest dose tested, 0.01 mg/kg-day (Table 3, Section III.D). While there were no FOB effects measured in the study, it is unknown if the brain changes observed could potentially cause long-term neurobehavioral changes.*

*OEHHA concurs with US EPA on their concerns about developmental neurotoxicity. US EPA published a systematic literature review on the neurodevelopmental toxicity of OPs supporting a policy decision to apply an additional 10-fold FQPA safety factor to human risk assessments for all OPs (US EPA, 2015b). The basis for their concern were in vivo laboratory studies demonstrating long term behavioral effects from early life exposures as well as multiple human epidemiology studies showing associations between OP exposure and developmental neurobehavioral effects in young children. US EPA determined that there was sufficient uncertainty regarding the mode of action and the human dose response relationship of OPs and DNT to support the 10-fold UF. They applied this additional UF in their risk assessment for dicrotophos (US EPA, 2015a).*

*OEHHA agrees that brain ChEI is a preferable endpoint for deriving a POD than a small, albeit statistically significant increase in absolute brain weight (Brammer, 2003). However, the effects on brain weight and morphometric measurements from the Brammer study heightened the concern on DNT. Therefore, OEHHA suggests that DPR apply an additional 10-fold UF to protect against DNT in the sensitive population.*

**HHAB Response:** HHAB agrees an additional uncertainty for infants, children, and women of childbearing age seems appropriate given the systematic review by U.S. EPA of possible effects of OPs on neurodevelopment by non-ChEI MOAs. These effects are not well understood at this time. However, it is not clear if the apparent increase in brain weights seen in pups in the DNT

study is related to ChEI. This effect was only statistically significant at 0.4 mg/kg/day, a dose level which should have caused significant brain ChEI based on the comparative ChE study in PND8 pups (Moxon, 2003). In the Moxon study, there was significant brain ChEI at 0.3 mg/kg (males: 42%; females: 34%). The evidence in this developmental neurotoxicity study for treatment related changes in morphometric measurements is not compelling. Although these differences were statistically significant, they were not consistent in either the regions affected or the direction of change (increased and decreased) between sexes or between days examined. Since these measurements were only performed in the controls and high dose group, there is also uncertainty about the dose response relationship. So while HHAB supports the use of an additional 10X UF for infants, children, and women of childbearing age based on U.S. EPA's systematic review, we do not believe the evidence from the DNT study can be used as further evidence in support of developmental neurotoxicity.

### **III.G. Worker and Bystander Exposure Assessment**

#### **III.G.1. Occupational Exposure Scenarios**

##### **III.G.1.a. Handlers**

*Acute and seasonal occupational handler (applicators, mixer/loaders, flaggers) exposures were estimated via the PHED. Based on monitoring study data, PHED provides generic exposure estimates for specific uses which are not chemical-specific. A major underlying assumption for these estimates is that worker exposure is primarily a function of the formulation type and the handling activities (e.g., packaging type, mixing/loading/application method or clothing scenario), rather than chemical-specific properties.*

*Since 2011, US EPA has replaced PHED with the Occupational Pesticide Handler Unit Exposure Surrogate Reference Table (OPHUESRT), which combines PHED point estimates with additional data from industry sources (US EPA, 2015c). However, DPR defines PHED-derived exposure estimates as the 90% UCL on the 95th percentile for short-term exposure and the 90% UCL on the arithmetic mean for intermediate- and long-term exposures. A known effective sample size is required to calculate both the 95th percentile and 90% UCL (DPR, 2007), and these data are not included in OPHUESRT.*

*OEHHA concurs with DPR's approach to calculating acute and long-term exposure estimates and agrees that exposure estimates based on PHED data are reasonable.*

*OEHHA is concerned with the continued reliance on PHED due to its acknowledged shortcomings. OEHHA commends DPR's decision to review newer studies included in OPHUESRT for use in later EADs.*

**HHAB Response:** U.S. EPA published the Occupational Pesticide Handler Unit Exposure Surrogate Reference Table (U.S. EPA, 2015), summarizing agricultural handler exposure estimates based on studies collected by the Agricultural Handler Exposure Taskforce (AHETF), the Outdoor Residential Exposure Task Force (ORETF), the Pesticide Handler's Exposure

Database (PHED), and other available registrant-submitted exposure monitoring studies. Of the 2 ORETF and 8 AHETF scenarios reviewed and accepted by U.S. EPA, only the “Closed Cockpit Aerial Application” applies to this EAD.

AHETF provided DPR with the AHETF worker exposure database, which HHAB is in the process of reviewing for use as surrogate handler exposure estimates when chemical-specific data is unavailable. Once completed, the dicrotophos EAD will be updated based on the AHETF data. The uncertainties attributed to PHED data for the development of exposure estimates will be considered during the mitigation phase.

*OEHHA recommends DPR identify the specific PHED scenarios used in this draft EAD to provide additional transparency to the analysis and consider including both PHED data and related calculations as a separate appendix. Recent draft EADs included all this information in a separate appendix instead of simply citing a memorandum containing all PHED scenarios.*

**HHAB Response:** PHED scenarios and calculations for absorbed daily dose are referenced in the current table footnotes. However, to improve transparency, Appendix I has been added to the revised EAD, which includes PHED data subsets and detailed mean dermal exposure calculations with protection factors.

### **III.G.1.b. Reentry Workers**

*Although hand weeding and thinning activities may also result in potential reentry worker exposure, cotton scouting is considered a crucial factor in limiting crop losses. Scouts handle and collect samples as frequently as twice a week (UGA, 2015). For dicrotophos, the current reentry interval (REI) is 6 days, the pre-harvest interval (PHI) is 30 days and the minimum application interval between applications is 14 days. Short-term dermal exposure estimates for cotton scouts assumed that reentry occurred no earlier than 6 days post-application based on the REI. Seasonal exposure was based on a DFR calculated for 13 days post-application (REI + 7 days).*

*OEHHA is concerned that DPR evaluated the cotton scouting scenario only at or after the 6-day post-application REI and did not consider exposure that may occur earlier. Some cotton industry guidance states that fields should be scouted every 5-7 days and that some scouts may inspect twice a week (UGA, 2015; Monk et al., 2012; Bacheler, 2012). Within the REI, cotton scouts would be required to use personal protective equipment (PPE) but the DFR would be expected to be higher. OEHHA recommends that DPR provide acute and seasonal estimates of cotton scout exposure, assuming a reasonable frequency of post-application re-entry prior to expiration of the REI.*

**HHAB Response:** Early reentry prior to expiration of the REI by cotton scouts has been addressed in the revised EAD. Potential short-term exposures were estimated for the first-day post-treatment for cotton scouts entering treated fields prior to the expiration of the REI while utilizing required PPE. These exposures were found to be lower ( $3.76 \times 10^{-3}$  mg/kg/day) than those of scouts entering treated fields without PPE 6 days post-application ( $5.05 \times 10^{-3}$

mg/kg/day). Thus, acute and seasonal exposures of cotton scouts wearing defined PPE during early reentry are expected to be lower than exposures calculated for scouts entering after the REI. With the exception of sweet corn, pest control/crop advisors reported scheduling inspection to avoid field entry during REIs (Spencer *et al.*, 2006). The crop advisors also reported informing scouts of fields under REI and scheduling scout inspections around REIs.

*DPR selected a DFR from a Texas field study (Prochaska, 1998) due to concerns about rainfall impacting study results. OEHHA concurs with the choice of the Texas study data for DFR estimation.*

*DPR used a TC of 2000 cm<sup>2</sup>/hr derived from studies of cotton scouts based on dermal exposure to three organophosphate pesticides (DPR, 1990), when estimating dicrotophos dermal exposure. OEHHA is concerned that the TC used in the draft EAD, while more health-protective than the value used by US EPA (US EPA, 2013b), may still lead to underestimation of dermal exposure.*

*Instead of using a TC derived from an analysis of three different pesticides, OEHHA recommends that DPR consider applying a TC derived with only the monocrotophos data, found in the same analysis cited in the draft EAD (DPR, 1990). Monocrotophos is a structural analog of dicrotophos, and the chemical and physical properties of these two compounds are very similar. OEHHA has determined that if the TC was based only on the monocrotophos data, the estimated exposure for cotton scouts would increase by 2.3-fold above the exposure estimate calculated in the draft EAD (Table 4).*

**Table 4. Mean dermal transfer coefficients (TC) for cotton scouts by body part.**

	<b>Mean TC (cm<sup>2</sup>/hr) from 3 pesticides** (DPR, 1990)</b>	<b>Mean TC (cm<sup>2</sup>/hr) Monocrotophos data (DPR, 1990)</b>
Bare Hands	950	1824
Upper Body*	102	983
Lower Body*	964	1757
<b>Total TC</b>	<b>2016</b>	<b>4564</b>

\* Includes 90% protection factor, TC= transfer coefficient

\*\* The three pesticides are monocrotophos, ethyl parathion, and methyl parathion.

**HHAB Response:** Upon considering the source of data for the Dong (1990) analysis, it was noted that the TC values derived measuring monocrotophos and ethyl and methyl parathion (Ware *et al.*, 1975) were “inconsistently higher” than those from Ware *et al.*, 1973; 1974. They were also higher than the typical TC values of reentry tasks that are similar to cotton scouting. For this reason, the geometric mean, rather than the arithmetic mean, was used by the original reviewer to reduce the impact of these unusually high values on the calculated surrogate TC value for use in estimating dermal exposures for cotton scouts (Frank, 2009). In addition to being unexpectedly high, the monocrotophos data were limited to only two time points, 48 and 72 hours.

Due to these uncertainties in the data, TC approximations using the monocrotophos data alone were not deemed to be better surrogates than those calculated from the geometric means of the three individual pesticides. As it stands, the TC value of 2000 cm<sup>2</sup>/hr used in this EAD is almost 10 times higher than that used by U.S. EPA (210 cm<sup>2</sup>/hr). The unacceptable exposure levels will be further addressed during the mitigation phase.

### **III.G.2. Residential Exposure of Adults and Children to Spray Drift**

*A major area of concern in this draft EAD and recent US EPA guidance is the off-target drift and deposition of dicrotophos onto residential or public areas with the potential for direct and indirect exposure of adults and children (US EPA, 2013a; US EPA, 2014a; US EPA, 2014b).*

*In spray drift-specific guidance, US EPA stated that “for regulatory purposes... this document focuses on compliant application events. In compliant application events no individual should be directly sprayed, given existing label language and requirements for worker protection, which means direct dermal and inhalation exposures to sprays will not be considered” (US EPA, 2013a). DPR’s rationale differed from that of US EPA in that DPR chose to estimate direct inhalation exposure when it was possible to do so (for aerial applications). OEHHA supports DPR’s decision and suggests the draft EAD discuss the rationale for including estimates of direct inhalation exposure.*

**HHAB Response:** We have updated the text in the RCD to reflect the change as suggested. That is, during pesticide spraying, the spray plume could drift off-site via advection and contaminate the nearby areas via deposition. Accordingly, inhaling the airborne pesticide prior to its deposition and (or) contacting the contaminated surfaces after its deposition are the potential exposure pathways. Unlike agricultural handlers, the existing label language on Restrictive Entry Interval (REI) does not apply to bystanders. Hence, even though the aerial application of pesticide is in compliance with the product label, exposure pathways including inhalation could potentially occur.

*In the draft EAD, specific inputs such as meteorological conditions and field size were used to give the highest deposition and air concentration estimates for spray drift under California conditions. OEHHA concurs with DPR’s use of these “worst-case” assumptions in estimating dicrotophos exposure from spray drift.*

*DPR chose two sentinel populations: Children 1-2 years of age and adults. DPR employed the modified US EPA Standard Operating Procedure for Residential Pesticide Exposure Assessment (US EPA, 2013a) in estimating the residential exposure to spray drift. OEHHA concurs with these choices.*

*Recently, US EPA released a preliminary screening level analysis for bystander exposure to volatilized conventional pesticides and dicrotophos was shown to exceed the concentration of concern for the cole crop scenario at all field sizes (US EPA, 2014e).*



*OEHHA is concerned about this additional exposure pathway for residential bystanders, particularly since dicrotophos use will occur during the warmest months of the year in the three Southern California counties where dicrotophos use is being proposed. OEHHA recommends that DPR discuss whether inhalation of dicrotophos vapor would contribute materially to the aggregate exposure for residential bystanders.*

**HHAB Response:** Vapor phase dicrotophos could derive from deposited material via volatilization. At the time this assessment was conducted, dicrotophos flux data was lacking. Unfortunately, the same data gap persists. However, based on the saturated vapor pressure of dicrotophos (i.e.,  $1.6 \times 10^{-4}$  mmHg), the theoretical maximum concentration can be estimated as 0.21 ppm (or 2040  $\mu\text{g}/\text{m}^3$ ) and an inhalation dose of 0.57 mg/kg/day based on a normalized adult breathing rate of 0.28 mg/kg/day. Hence, under the actual field conditions, the inhalation exposure due to volatilized dicrotophos vapor might not be negligible. Nevertheless, since the aggregated MOE is below the benchmark of 100 without considering volatilization, the inclusion of vapor dicrotophos to the aggregated exposure for residential bystanders will not change the overall conclusion.

### **III.G.2.a. Spray Drift Exposure Estimates from Aerial Applications**

*The AGDISP model, which tracks droplets and adjusts for turbulence, evaporation and weather conditions (Teske et al., 2002), was used to calculate all inhalation and deposition estimates for adults and children near aerial application sites. Estimates were generated for two application rates and two types of aircraft. Details of the application input parameters used in the draft EAD can be found in a separate memorandum (DPR, 2015a) and closely match those found in draft US EPA guidance documents (US EPA, 2013a; US EPA, 2014f).*

*The AGDISP software used in the draft EAD differs functionally from the AgDRIFT software used in the US EPA 2014 dicrotophos exposure assessment. AgDRIFT algorithms were designed primarily to model the motion of large droplet distributions (US EPA, 2014b; Teske et al., 2009). Recent versions of AGDISP incorporate updated algorithms that more accurately predict fine droplet motion, resulting in greater near field (< 400m) deposition and a decrease in far field (> 400 m) deposition (Teske et al., 2009).*

*OEHHA concurs with DPR's aerial spray drift model selection, input parameters and the resulting exposure estimates.*

### **III.G.2.b. Spray Drift Exposure Estimates from Ground Applications**

*Only indirect dermal and oral exposures were estimated for ground applications. Since the AgDRIFT groundboom module is based entirely on field study data to predict spray drift deposition, it is not able to estimate air concentrations (Teske et al., 2002).*

*As described in a supporting memorandum, DPR used two boom heights, a fine-to-medium/coarse droplet spectrum distribution and the 50th percentile options in estimating exposure. The rationale stated by DPR for choosing the 50th percentile was to "maintain*

*uniformity with orchard airblast” and the “derivation of the 90th percentile is not clear” and the AgDRIFT documentation provided insufficient mathematical detail (DPR, 2015a).*

*OEHHA is concerned about the choice of input parameters for estimating groundboom-related spray drift deposition. The US EPA chose more conservative options (fine to very fine spray inputs and outputs based on the 90th percentile deposition curve) in their exposure assessment (US EPA, 2014b) that resulted in risk estimates for children at distances of 50 feet or less, while the DPR analysis found only exposures of concern at 25 feet.*

**HHAB Response:** Ground boom estimates were not produced using medium/coarse droplet spectra. The AgDRIFT ground boom scenarios were run using Very Fine/Fine droplet spectra nozzles and both low and high boom scenarios were run. Please see Table A-1 on page 113 of the revised EAD where the droplet spectra employed each scenario are listed. All droplet spectra choices were made according to label requirements.

*OEHHA agrees that the AgDRIFT user manual does not fully document the calculation of the 90th percentile estimates for groundboom. However, it does contain the curve-fitting formula and curve shape parameters used in the data analysis (Teske et al., 2003). Both the AgDRIFT user manual, and the 1999 background document for the FIFRA SAP review of the AGDRIFT groundboom module indicate that these deposition curves were based on the measured values that bounded either 50% or 90% of the data at each distance (Teske et al., 2003; US EPA, 1999a).*

*OEHHA recommends that DPR provide additional rationale for these choices and cite any additional references which would support the use of the medium/coarse droplet size distribution. OEHHA also recommends that DPR use the more conservative 90th percentile output option as the ground application deposition algorithms were evidently based on measured values that bounded the data at each point (US EPA, 1999a; US EPA, 1999b; Teske et al., 2003).*

**HHAB Response:** Please refer to the above response and the response to comment #7 for Section I.B.3 starting on page 9 of this document.

*The draft EAD states that “studies showed that the ambient air concentrations of other organophosphates (e.g., chlorpyrifos) measured after a ground-based application could be similar (within a factor of ~2) to the simulated values from an aerial application of chlorpyrifos (CARB, 1998).” The cited chlorpyrifos field study data appear to be from an airblast application at an orange grove at an application rate of 6 pounds AI/acre.*

**HHAB Response:** Based on the draft chlorpyrifos RCD, available data suggest that air concentration produced via aerial and orchard airblast application methods could be within a factor of two. In the absence of experimental data, this example may provide an insight on the uncertainty of inhalation exposure estimates.

*OEHHA is concerned with the apparent lack of approved methodology available for estimating air concentrations for nearby groundboom applications. If inhalation exposure from groundboom*

*was roughly estimated as 25-50% of the estimated aerial inhalation exposure, then the aggregate dose would be larger for some of the groundboom exposure scenarios.*

**HHAB Response:** This type of conclusion illustrates why the ground boom 50<sup>th</sup> percentile modeling results should be used to characterize exposure due to ground boom applications. It is inappropriate to compare ground boom 90<sup>th</sup> percentile deposition plus potential inhalation exposures to the aerial ensemble mean deposition plus potential inhalation exposures. The modeled 50<sup>th</sup> percentile ground boom deposition is less than the aerial ensemble mean deposition. Therefore, adding 25-50% of the aerial inhalation estimate to the ground boom will not result in the aggregate dose for ground boom exceeding aerial aggregate dose.

*OEHHA recommends that DPR provide a comparison of estimates or range of estimates from both simulated and field study sources to further clarify this point. OEHHA also recommends that DPR consider using AGDISP or other methods to estimate air concentrations for nearby ground applications. A recent study demonstrated that AGDISP v8.27 air concentration estimates closely approximated measured concentrations from application site air sampling data (Nsibande et al., 2015), while a box model approach may not be suitable for this exposure scenario (US EPA, 2014d).*

**HHAB Response:** DPR has been cautious about using the AGDISP ground boom model because it has not been fully vetted. The AGDISP ground boom model comparisons with field data have shown various discrepancies, including significantly over or under predicting horizontal deposition depending upon the distance downwind (Woodward, 2008; Teske *et al.*, 2009) and an inability to reasonably estimate vertical flux when compared to measured values (Connell *et al.*, 2012). The most recent AGDISP ground boom paper (Nsibande *et al.*, 2015) models only air concentrations for a ground application made to a 0.9 m sorghum field. The study did not measure deposition. The presence of a crop canopy complicates the modeling because type and density of the crop canopy introduces many more variables into the modeling. In fact, the AGDISP ground model does not include a canopy effect algorithm (Teske *et al.*, 2009). Figure 2 of Nsibande *et al.* (2015) indicates a linear relationship between modeled and measured air concentrations. However, it is also clear from Figure 2 of Nsibande *et al.* (2015) that how well the magnitude of the modeled air concentrations match measure air concentrations is sensitive to the fraction of the nozzle droplet spectrum less than 141  $\mu\text{m}$  (the driftable fines) and the height at which the air concentrations are measured. This is evident from the non-parallel regression lines for nozzle types and the slopes values at different heights within nozzle type. Meaning that the model performance is highly dependent upon what nozzle is simulated and at what height the air concentration is estimated. Therefore, it is impossible to evaluate in practice how well the model performs in scenarios beyond those presented in Nsibande *et al.* (2015). OEHHA is correct in speculating that a box model approach is not suitable for the ground boom exposure scenario.

### **III.G.3. Other Non-occupational Exposure Scenarios Not Addressed in the Draft EAD**

*Exposure to “take home” indoor dust was not addressed by the draft EAD. Homeowners, farmworkers, and their families may be exposed to dicotophos via “take home” dust exposure. A number of studies suggest that incidental (non-dietary) ingestion of pesticide-contaminated dust may occur frequently in the homes of California farmworkers (Bradman et al., 2007; Quirós-Alcalá et al., 2011). OEHHA recommends that “take home” dust exposure be discussed in the draft EAD.*

**HHAB Response:** Homes in proximity to pesticide-treated farmlands were found to have higher OP pesticide residues in house dust, suggesting pesticide drift to be a contributor to residential exposures (Simcox *et al.*, 1995; Lu *et al.*, 2000; Fenske *et al.*, 2002). To a lesser degree, pesticide levels of house dust were also associated with the “take home” scenario where pesticide residue are transferred from the workplace via work clothing, shoes, vehicles, and tools. Although pesticide residues in household dust appear to be a source for residential exposure, particularly for young children, urinary metabolites of OP pesticides were not shown to be clearly associated with household dust levels (Lu *et al.*, 2000; Fenske *et al.*, 2002).

Mixers/Loaders and applicators are required to use closed systems to minimize exposure to dicotophos. In addition, the label instructs users to remove and replace contaminated clothing and keep/wash the PPE separate from other laundry. Clothing that has been drenched or heavily contaminated is to be discarded and not reused. Such procedures are expected to minimize “take home” residues of dicotophos in residential settings.

### **III.H. Dietary Exposure Assessment**

*The dietary exposure assessment was included in the main body of the draft RCD. The analysis included acute and steady-state exposures to dicotophos in food, drinking water, and combined exposures. Exposure estimates included subgroups of the population segregated out by age, sex, and workers status.*

*There are only two tolerances established for dicotophos residues in food, cottonseed (0.2 ppm) and cotton gin by-products (2 ppm). Exposures were calculated based on a residue value for cottonseed oil, the only food product consumed by people resulting from dicotophos treatment of the cotton plant.*

#### **III.H.1. Residue Data**

##### **III.H.1.a. Food Residues**

*DPR used cottonseed residue data from two registrant submitted studies (Prochaska, 1998a; Prochaska, 1998b). One study analyzed raw commodities (undelinted cottonseed and cotton gin by-products) while the other study analyzed the processed cotton products (refined cottonseed oil, meal, and hulls). The studies were not described in detail in the draft RCD. It is unclear which commodities, or if all commodities had residues and what the residues were. DPR stated*

*that the two studies gave an average of 0.0367 ppm for cottonseed oil (the end product consumed by humans) and used this value in acute and steady-state dietary exposure. However, only one of the two residue studies are described as including cottonseed oil among the commodities analyzed. OEHHA questions the approach used in calculating the residue level in cottonseed oil. US EPA used a cottonseed oil residue value of 0.043 ppm in their 2015 risk assessment but did not report the source of the data. OEHHA suggests DPR provide additional description of the residue studies and provide justification for how the cottonseed oil residue value was determined. DPR may also wish to contact USEPA to get their source of cottonseed oil data.*

**HHAB Response:** HHAB has added more detail about the residue studies used in the dietary exposure assessment. In reviewing these residue studies again, we have changed how the average residue value was derived. As before, the residue values are from undelinted cottonseed rather than refined cottonseed oil because only one sample from one site was tested in the processed commodities study. In addition, we decided to only use residue values from sites in drier locations like California since higher rainfall appears to significantly reduce the residue levels. Consequently, only samples from California (3 sites, 2 samples from each), New Mexico (1 site, 2 samples), Oklahoma (1 site, 2 samples) and northwestern Texas (2 sites, 2 samples from each) were included in the average. Samples from Arkansas, Georgia, Louisiana, Mississippi, and southeast Texas (2 samples from each site) had residues at or below the LOD and were not included in the average.

### **III.H.1.b. Drinking Water Concentration**

*DPR used dicrotophos levels in finished drinking water (post-treatment ready for consumption) samples from USDA's PDP 2008-2013 to estimate the drinking water exposure. Monitoring data before 2008 were not used because the detection limits were 10- to 100-fold higher than the current values. Residue values (400 samples) from multiple states were used to develop the distribution needed for the probabilistic assessment. However, of the 400 samples, only four were detects, ranging from 1.5 to 3.4 parts per trillion (ppt) and the LOD was 0.9 ppt. Given the quality of the database, OEHHA questions the benefit of conducting the probabilistic assessment of drinking water exposure.*

**HHAB Response:** The main limitation of the PDP database is the possibility of missing peak values because of the infrequency of sampling, not how the samples were handled or analyzed. However, there is value gained from this analysis, even if only to establish a lower bound for drinking water exposure.

*US EPA in their 2014 and revised 2015 risk assessments for dicrotophos estimated both surface water and ground water exposure concentrations. The estimated surface water concentrations were orders of magnitude higher than estimated for groundwater and were chosen as the driver for risk. OEHHA agrees with DPR that surface water exposure estimates grossly overestimate drinking water exposure and agree with DPR's choice to use finished drinking water samples as most appropriate because it is more commonly consumed by the public. However, because of the very large differences between surface, ground, and finished*

*drinking water estimates, additional justification for choosing the least conservative of the 3 should be included. Because dicrotophos is water soluble and has been detected in the groundwater of some other states (US EPA, 2015a), OEHHA also suggests DPR include a discussion on the potential for dicrotophos to contaminate groundwater.*

**HHAB Response:** An environmental fate section has been added to the dicrotophos RCD. Included in this section are the physical-chemical properties that DPR considers when listing a pesticide as a potential groundwater contaminant. The water solubility, hydrolysis rate and  $K_{oc}$  values reported by U.S. EPA and/or HSDB exceed DPR's specific numerical values (SNVs) for listing dicrotophos as a groundwater. However, dicrotophos is not listed by DPR as a potential groundwater contaminant because it is not currently registered in California. Despite SNV exceedances, no dicrotophos residues have been detected in almost 5,000 wells sampled since 1990 by the Nationwide Water-Quality Assessment Program (NAWQA). On the other hand, surface water residues have been detected by USGS in the Mississippi Embayment. Discussion of the groundwater and surface water monitoring conducted by other agencies is included in the environmental fate section of the RCD.

### **III.H.2. Exposure Calculation**

#### **III.H.2.a. DEEM-FCID**

*The DPR draft dicrotophos dietary exposure assessment derived exposure estimates using DEEM-FCID v. 3.16, which used National Health and Nutrition Examination Survey (NHANES) dietary consumption data from 2003-2008. A more recent version of DEEM-FCID (v. 4.02) is available and uses consumption data from 2005-2010. DEEM-FCID v. 4.02 has two out of six years of more recent data relative to v. 3.16. Because consumption rates are only needed for one commodity (cotton seed oil) and because cottonseed oil is a blended commodity typically used in small amounts in various food products, it is unlikely that consumption of cottonseed oil will have changed substantially from 2003-08 to 2005-2010. However, OEHHA suggests using the most current data and software to derive exposures.*

**HHAB Response:** U.S. EPA used the DEEM-FCID version 3.16 in both their 2014 and 2015 dietary and drinking water assessments. The DEEM-FCID 4.02 version was still being beta-tested by U.S. EPA when the dicrotophos RCD review draft was completed, so it was not used even though it was available. Due to this comment, HHAB contacted David Hardy at U.S. EPA and learned that the beta testing of the 4.02 version is nearing completion. The final version should be released in December 2016, but he indicated no numerical differences are expected between the beta-test 4.02 version and the final version. Since HHAB is redoing the dietary analysis due to a change in the cottonseed oil residue value, we decided to rerun it with the 4.02 version. A comparison of the output with the two different versions was made using the same residue values and the differences are minor taking into consideration that the cottonseed residue value increased.

*DPR used the two-day average food consumption data from NHANES for estimating the acute exposure. OEHHA disagrees with this approach as it would lead to under-estimating the*

*exposure. OEHHA recommends using the one-day consumption data of consumers only. Two-day averages are more appropriate for steady-state exposure scenarios.*

**HHAB Response:** For most participants, there are two days of records from the NHANES survey. In the DEEM-FCID Acute Analysis program, these two days can be treated as separate events or averaged. In this risk assessment for dicotophos, the acute exposure was estimated by treating these two-day food records as separate events (program default unless the two-day average is selected) and the 95<sup>th</sup> percentile of those single day exposures among users was reported. For steady state exposure, the Acute Analysis program was still used, but the two-day average option was selected and the mean value for users was reported rather than the 95<sup>th</sup> percentile. The strength of using the Acute Analysis program for chronic exposure estimates is that one can select users only or custom populations. The exposure estimates based on the 2-day mean per capita are identical to the exposure values generated in the Chronic Analysis program. The RCD has been revised to include more explanation of these analysis options.

### **III.H.2.b. Subpopulations**

*The current dicotophos dietary exposure assessment does not include an evaluation of pregnant women. Because there is a concern for DNT, it would be prudent to include this sensitive population.*

**HHAB Response:** Pregnant women are included in the exposure estimates for women of child bearing age (13-49 yrs old). Generally, their consumption is not that different from non-pregnant women. Lactating women, however, can have much higher exposures because of higher food consumption during that time (more so than during pregnancy). However, DEEM-FCID no longer includes nursing women as a standard population subgroup and if one tries to create a custom population subgroup with just nursing women, it has no women in that group. This was true for both versions of DEEM-FCID. It seems unlikely that NHANES did not include a single nursing woman, so it may be a problem with these versions of DEEM-FCID.

### **III.H.2.c. "Workers 18-99"**

*Tables 8 and 9 in the draft EAD presented exposure estimates and MOEs for various subpopulations including "workers 18-99" years old. Elsewhere in the document "workers" refers to occupational exposures. It is unclear how "worker" food and water consumption data were derived from the NHANES dataset. OEHHA recommends the procedure be better described or this group be removed.*

**HHAB Response:** The "Workers -18-99 years old" population subgroup was a custom population subgroup derived for aggregating worker occupational exposure with their dietary and drinking water exposure. This consumption was derived in the DEEM-FCID Acute Analysis program by clicking on one of the boxes under the Custom Population option, giving it a name and then defining the population by gender, age, ethnicity and whether they are pregnant or nursing. This custom subpopulation group included both sexes, ages 18-99 years old, all races,

and all women regardless of whether they were pregnant or nursing. Since the dietary and drinking water exposure estimates for this custom population were also used for adult bystanders the name was changed to “Adults – 18+yrs” which should be less confusing.

### **III.H.2.d. Exposure Percentiles**

*The exposure estimates used to calculate MOEs for each acute and steady state exposure from dietary (food only), drinking water, and combined (dietary plus drinking water) pathways are listed in Table 8 of the draft EAD. This table shows that a 95th-, a 99.9th-, and a 97.5th-percentile value was used for dietary, drinking water, and combined exposures, respectively. OEHHA recommends the reasoning for selecting these percentiles be provided in the RCD. The method by which the combined exposure estimates in Table 8 were derived was not explained. OEHHA suggests DPR provide a clear description of how the combined exposure estimates (dietary plus drinking water) were calculated.*

### **III.I. Risk Characterization**

#### **III.I.1. Targets for Acceptable Risk**

*DPR considered the target MOE of 100 (which is the total UF) as health protective for all exposure groups and durations. This was based on 10-fold UF for interspecies extrapolation and 10-fold for intraspecies variability. As previously discussed, OEHHA recommends the target MOEs of 300 for the general adult population and 1000 for the sensitive population. The same UFs should be applied for acute and steady state exposures of all routes.*

**HHAB Response:** As discussed earlier, HHAB is recommending a default uncertainty factor of 100 for intraspecies and interspecies variation and an additional UF of 10X for sensitive subpopulations including infants, children and pregnant women. So HHAB is in agreement regarding the uncertainty factor for sensitive population subgroups, except whether these include the elderly, but use different default for the general adult population (100).

#### **III.I.2. Combined Exposure**

*In the draft RCD, acute exposures to dicotophos by multiple routes (referred to as combined exposures or aggregate exposure) were evaluated for three scenarios: (1) dietary and drinking water for all population subgroups, (2) dermal and inhalation, exposures for workers and adult bystanders, and (3) dermal, inhalation, and incidental oral exposures (hand-to-mouth exposures) for child bystanders. The combined exposures were calculated using the MOEs for the individual routes. OEHHA agrees with this approach since all the PODs were based on the same endpoint, brain ChEI. However, OEHHA recommends DPR provide explanation for not including the dietary route in the combined exposures for workers and bystanders.*

**HHAB Response:** An aggregate exposure assessment was performed for this revised draft of the RCD for dicotophos. New Aggregate Exposure subsections have been added to the Exposure Assessment section and the Risk Characterization section even though aggregating



these exposures did not significantly increase the risks for either workers or bystanders. Generally, the dietary and drinking water exposures only significantly changed the combined MOE when the MOEs for workers or bystanders were greater than 1,000 and not a concern. In these cases, the aggregated MOEs were still greater than 1,000.

#### **IV. MINOR COMMENTS**

##### **IV.A. Draft RCD (Dietary and Drinking Water Exposure)**

*Page 5: "Conclusions" section should go after "Risk Appraisal" section.*

*Page 15: "Only 4 samples from North Carolina in 2012 had detectable residues..." For clarity, OEHHA suggests the sentence be revised to "The only detectable residues were 4 samples from North Carolina in 2012..."*

**HHAB Response:** HHAB does not agree that the suggested revision improves the clarity of the sentence, so it was not changed.

*Page 17: In Table 8, the combined steady-state exposure for infants is less than the food only steady-state exposure. This is likely a typo. OEHHA suggests reviewing the infant values in this table and revising as necessary.*

**DPR RAS Response:** The difference in "combined steady-state" and "food only steady-state" values is an artifact of the DEEM modeling. Such an outcome is more likely when adding commodities when analyzing user exposure estimates. This is much less likely to occur when using per capita exposure. The reason that the combined value is less than the food-only value is the user population increases with additional commodities and, consequently, the consumption at a given percentile will go down. So despite using a higher percentile for aggregated food and water consumption, the user exposure estimate at the 97.5<sup>th</sup> percentile was lower than the user exposure estimate for food alone at 95<sup>th</sup> percentile. If the per capita consumption for all infants is compared, the combined food and water exposure is higher (steady state food only: 0.840 ng/kg/day; food + water: 0.911 ng/kg/day). This is a confusing aspect of reporting per user exposure estimates rather than per capita estimates. However, it is HHAB's practice to use the per user estimates because these values are higher and, therefore, more health protective.

*Page 21: "The acute exposure estimates ranged from 1.63 ng/kg/day for adults 50-99 years old to 6.93 ng/kg/day for children 1-2 years old. The steady state exposure estimates were about a third lower ranging from 0.58 ng/kg/day for adults 50-99 years old to 2.58 ng/kg/day for children 3-5 years old." OEHHA observes that the steady state exposure estimates are approximately a third of the acute estimates rather than one third lower. OEHHA suggests that the wording be revised to clarify the sentence.*

**HHAB Response:** OEHHA is correct and this phrase was reworded to: "The steady state combined exposures were about one third of the acute exposures."

*The draft DPR 2015 dicotophos assessment refers to “dietary” as food only while some other DPR assessments refer to “dietary” as food plus drinking water (e.g., 2015 draft methomyl RCD, 2015 draft chlorpyrifos RCD). This comment is informational only, to help if departmental consistency is desired.*

**HHAB Response:** Noted.

#### **IV.B. Draft EAD**

*In the exposure appraisal (page 23, last paragraph), the phrase “studies showed” may imply that the two-fold difference in chlorpyrifos air concentrations between aerial and ground applications was observed experimentally and does not indicate that the air concentrations due to aerial applications were simulated (DPR, 2015a). The draft EAD should be revised to read “comparison of modelled air concentrations and field study data from ground applications”.*

**HHAB Response:** The EAD has updated to address this comment.

*The title of the Barry reference (DPR, 2015a) should be corrected as the title is “Estimation of Chlorpyrifos Horizontal Deposition and Air Concentrations for California Use Scenarios”.*

**HHAB Response:** This is the correct title for the reference. The dicotophos estimate method was based on those for chlorpyrifos.

*On page 24 of the exposure appraisal, (paragraph 2), the draft EAD stated, “Both Agencies employed the same modeling parameters for simulating drift exposures due to groundboom.” This is incorrect. US EPA used a “very fine to fine” spray type in the dicotophos exposure assessment for groundboom (US EPA, 2014b).*

**HHAB Response:** As stated earlier, this observation by OEHHA is incorrect. DPR used the very fine to fine spray quality to model the ground boom scenario. Please refer to Table A1 in Appendix II of the revised Exposure Assessment Document.

*In the description of the spray drift-bystander exposure scenarios, the supporting memorandum (DPR, 2015a) shows in Table 1 that the droplet distribution for groundboom exposure estimates was “medium/coarse”. However, the user manual for AGDRIFT 2.1.1, the choices for droplet distribution are shown as “very fine to fine” and “fine to medium/coarse”. This may be a typo or due to changes in the software between v2.0.05 and v2.1.1.*

*The website [www.agdrift.com](http://www.agdrift.com) is cited as the source for several references in the Barry memorandum but is no longer active.*

**HHAB Response:** The supporting memorandum modeling was conducted for chlorpyrifos, which has different label requirements. The analysis for groupings of ground boom spray quality was performed by DPR and is documented both in Barry 1999a, b and U.S. EPA 1999b.

Shelley DuTeaux  
December 22, 2016  
Page 43

The sprayer groupings were very fine to fine and medium to coarse. It is true that the model shows “Fine to Medium/Coarse” but there is no ASAE spray quality category between Fine and Medium. The dicotophos modeling states in Table A1 of Appendix II in the revised Exposure Assessment Document that very fine to fine spray quality was used to model ground boom.

## References

- Barry, T., 1999a.** Data analysis and exposure assessment. Presented at the July 1999 FIFRA SAP Session IV. Spray Drift - Review of proposed pesticide deposition curves to adjacent areas. *Unpublished Report.* pp.
- Barry, T., 1999b.** Ground Spray Report. Prepared for the July 1999 FIFRA SAP Session IV. Spray Drift - Review of proposed pesticide deposition curves to adjacent areas. *Unpublished Report.* pp.
- Barry, T.A., D.L. Valcore, and A.J. Hewitt, 1999.** The effect of droplet size and other variables on drift from applications of sprays by ground. 1999 International Meeting of the American Society of Agricultural Engineers. Toronto, Canada, July 18-21, 1999.
- Connell, R.J., W.C. Schou, Nuyttens, T.M. Wolf, and J.P. Praat, 2012.** Comparison of the mechanistic AGDISP ground boom spray model with experimental data. . *New Zealand Plant Protection* 65: 93-99.
- CottonJourney.com, 2015.** Story of Cotton. In *Cotton's Journey; Planting the Seeds of Knowledge*. <http://www.cottonsjourney.com/storyofcotton/page3.asp>, Hanford, California.
- Dong, M.H., 1990.** Dermal Transfer Factor for Cotton Scouts, Sacramento, CA.
- Fenske, R.A., C. Lu, D. Barr, and L. Needham, 2002.** Children's exposure to chlorpyrifos and parathion in an agricultural community in central Washington State. *Environ Health Perspect* 110(5): 549-553.
- Frank, J.P., 2009.** Exposure Assessment Policy and Procedure - Default Transfer Coefficients, Sacramento, California.
- Lu, C., R.A. Fenske, N.J. Simcox, and D. Kalman, 2000.** Pesticide exposure of children in an agricultural community: evidence of household proximity to farmland and take home exposure pathways. *Environ Res* 84(3): 290-302.
- NAFTA TWA, 2012.** Draft Report and Protocol: Use of In Vitro Dermal Absorption Data in Risk Assessment. Unpublished; Available upon request. pp.
- Nsibande, S.A., J.M. Dabrowski, E. van der Walt, A. Venter, and P.B. Forbes, 2015.** Validation of the AGDISP model for predicting airborne atrazine spray drift: A South African ground application case study. *Chemosphere* 138: 454-461.

- PMRA, 2011.** Indaziflam Proposed Registration Decision. PRD2011-20. Ottawa, Ontario. 7 October 2011. pp. ([http://publications.gc.ca/collections/collection\\_2011/sc-hc/H113-9-2011-20-eng.pdf](http://publications.gc.ca/collections/collection_2011/sc-hc/H113-9-2011-20-eng.pdf))
- PMRA, 2015.** Bicyclopyrone Proposed Registration Decision. PRD2015-02. Ottawa, Ontario. 13 February 2015. pp. ([http://publications.gc.ca/collections/collection\\_2015/sc-hc/H113-9-2015-2-eng.pdf](http://publications.gc.ca/collections/collection_2015/sc-hc/H113-9-2015-2-eng.pdf))
- Simcox, N.J., R.A. Fenske, S.A. Wolz, I.C. Lee, and D.A. Kalman, 1995.** Pesticides in household dust and soil: exposure pathways for children of agricultural families. *Environ Health Perspect* 103(12): 1126-1134.
- Spencer, J.R., A.M. Welsh, B.Z. Hernandez, C. Benson, S. Fredrickson, and V. Quan, 2006.** An Observation Study of Crop Advisors' Activities, Project 0202, Sacramento, CA.
- Teske, M.E., S.L. Bird, D.M. Esterly, T.B. Curbishley, S.L. Ray, and S.G. Perry, 2003.** A User's Guide for AgDRIFT® 2.0.07: A Tiered Approach for the Assessment of Spray Drift of Pesticides. (Prepared for David R. Johnson, P.M.S.d.t.f., Ed.). Stewart Agricultural Services, Inc. P.O. Box 509, Macon, Missouri 63552.
- Teske, M.E., P.C.H. Miller, H.W. Thistle, and N.B. Birchfield., 2009.** Initial development and validation of a mechanistic spray drift model for ground boom sprayers. . *Transaction of the ASABE* 52: 1089-1097.
- U.S. EPA, 1999a.** Background Document for the Scientific Advisory Panel on Ground Hydraulic Applications: Downwind Deposition Tolerance Bounds for Ground Hydraulic Boom Sprayers. Washington, D.C. pp. (<http://archive.epa.gov/scipoly/sap/meetings/web/pdf/boom.pdf>)
- U.S. EPA, 1999b.** Spray Drift - Review of Proposed Pesticide Deposition Curves to Adjacent Areas. SAP Report No. 99-04D. Washington, D.C. pp. (<http://archive.epa.gov/scipoly/sap/meetings/web/pdf/finlrpt4.pdf>)
- U.S. EPA, 2008.** Permethrin: Estimated dermal absorption factor in human. R162913. Washington, D.C. October 16, 2008. pp. ([https://www3.epa.gov/pesticides/chem\\_search/cleared\\_reviews/csr\\_PC-109701\\_16-Oct-08\\_a.pdf](https://www3.epa.gov/pesticides/chem_search/cleared_reviews/csr_PC-109701_16-Oct-08_a.pdf))
- U.S. EPA, 2010.** Review of the Triple Pack Dermal Absorption Studies for Maxim Quattro. R182519. Washington, D.C. June 2, 2010. pp.
- U.S. EPA, 2013.** Glufosinate Ammonium. Response to Comments on the Human Health Risk Assessment for Registration Review. Washington, D.C. October 29, 2013. pp.

- U.S. EPA, 2015.** Occupational Pesticide Handler Unit Exposure Surrogate Reference Table. September 2015. pp. (<http://www.epa.gov/sites/production/files/2015-09/documents/handler-exposure-table-2015.pdf>)
- van de Sandt, J.J., J.A. van Burgsteden, S. Cage, P.L. Carmichael, I. Dick, S. Kenyon, G. Korinth, F. Larese, J.C. Limasset, W.J. Maas, L. Montomoli, J.B. Nielsen, J.P. Payan, E. Robinson, P. Sartorelli, K.H. Schaller, S.C. Wilkinson, and F.M. Williams, 2004.** In vitro predictions of skin absorption of caffeine, testosterone, and benzoic acid: a multi-centre comparison study. *Regul Toxicol Pharmacol* 39(3): 271-281.
- Ware, G.W., D.P. Morgan, B.J. Estes, and W.P. Cahill, 1974.** Establishment of reentry intervals for organophosphate-treated cotton fields based on human data. II. Azodrin, ethyl and methylparathion. *Arch Environ Contam Toxicol* 2(2): 117-129.
- Ware, G.W., D.P. Morgan, B.J. Estes, and W.P. Cahill, 1975.** Establishment of reentry intervals for organophosphate-treated cotton fields based on human data: III. 12 To 72 hours post-treatment exposure to monocrotophos, ethyl- and methyl parathion. *Arch Environ Contam Toxicol* 3(3): 289-306.
- Ware, G.W., D.P. Morgan, B.J. Estes, W.P. Cahill, and D.M. Whitacre, 1973.** Establishment of reentry intervals for organophosphate-treated cotton fields based on human data. I. Ethyl- and methyl parathion. *Arch Environ Contam Toxicol* 1(1): 48-59.
- Woodward, S.J.R., R.J. Connell, J.A. Zabkiewicz, K.D. Steele, and J.P. Praat, 2008.** Evaluation of the AGDISP ground boom spray drift model. . *New Zealand Plant Protection* 61: 164-168.
- Wu, J.-C., S.M. Chye, M.K. Shih, C.-H. Chen, H.-L. Yang, and S.C. Chen, 2010.** Genotoxicity of dicrotophos, an orgnaophosphorous pesticide, assessed with different assays *in vitro*. *Environ. Toxicol.* 27(5): 307-315.